BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

```
     AT E1 V1 X0 DT93592500
     CONNECT
f`
Dialog Information Services' DIALNET
-2030:01-021-
Enter Service: DIALOG


DIALNET: call connected

DIALOG INFORMATION SERVICES
PLEASE LOGON:
 ******** HHHHHHHH SSSSSSSS ? ********
 ENTER PASSWORD:









 ******** HHHHHHHH SSSSSSSS ? ********

Welcome to DIALOG
Dialog level 29.01.09D

Last logoff:  26jan93 16:09:03
Logon file001 04feb93 11:15:36
COPR. (c) DIALOG INFORMATION SERVICES, INC. ALL RIGHTS RESERVED.
NO CLAIM TO ORIG. U.S. GOVT. WORKS.

New:  VIRGINIAN-PILOT/LEDGER-STAR (PAPERS) (File 741)
New:  INSWORLD R & D FOCUS (File 445) - Bluesheet available
      online in File 415

***TEXTLINE Files Restructured to TEXTLINE GLOBAL NEWS***
     (Files 799, 772, 771)
***Now Available - DIALOG RANK Command***


     ))) Enter BEGIN HOMEBASE for Dialog Announcements (((
     )))    of new databases, price changes, etc.      (((
```

File 1:ERIC 66-93/JAN

Set Items Description

?b 155,50,55,144,76

04feb93 11:16:05 User219509 Session D70.1
$0.29 0.038 Hrs File1
$0.29 Estimated cost File1
$0.09 DIALNET
$0.38 Estimated cost this search
$0.38 Estimated total session cost 0.038 Hrs.

SYSTEM:OS - DIALOG OneSearch
File 155:MEDLINE 1966-1993/MAR (9303W4)
File 50:CAB Abstracts 1984-1993/Jan
(c) 1993 CAB International
**FILE50: COPR. 1990 CABI. See HELPNEWS50 for CAB training schedule.
File 55:BIOSIS PREVIEWS 85-93/JAN BA9504:BARRM4404
(C. BIOSIS 1993)
**FILE 55: Biosystematic Codes (BC=) for viruses have changed for 1993.
Type ?NEWS55 for more information and a complete list of the new codes.
File 144:PASCAL 1973 - 1992 DEC
(C. INIST/CNRS 1992)
**FILE144: Limit problem: see ?news144
Update 9301 has been temporarily backed off due to duplicate records
File 76:LIFE SCIENCES COLLECTION 73-92/DEC

(Copr. Cambridge Scientific Abs.)

Set Items Description

?b 155,50,55,144,72,350,351

04feb93 11:16:36 User219509 Session D70.2
$0.03 0.001 Hrs File155
$0.03 Estimated cost File155
$0.06 0.001 Hrs File50
$0.06 Estimated cost File50
$0.10 0.001 Hrs File55
$0.10 Estimated cost File55
$0.06 0.001 Hrs File144
$0.06 Estimated cost File144
$0.09 0.001 Hrs File76
$0.09 Estimated cost File76
OneSearch, 5 files, 0.003 Hrs FileOS
$0.09 DIALNET
$0.43 Estimated cost this search
$0.81 Estimated total session cost 0.010 Hrs.

```
SYSTEM:OS  - DIALOG OneSearch
  File 155:MEDLINE  1966-1993/MAR (930304)
  File  50:CAB Abstracts  1984-1993/Jan
        (c) 1993 CAB International
 **FILE050:  COPR. 1990 CABI.  See  HELPNEWS50 for  CAB training
schedule.
  File  55:BIOSIS PREVIEWS  85-93/JAN BA9504:BARRM4404
        (C. BIOSIS 1993)
 **FILE 55:  Biosystematic Codes  (BC=) for viruses  have changed
for 1993.
 Type ?NEWS55 for more information and a complete list of the new
codes.
  File 144:PASCAL  1973 - 1992 DEC
        (C. INIST/CNRS 1992)
 **FILE144: Limit problem: see ?news144
Update 9301  has been  temporarily backed  off  due to  duplicate
records
  File  72:EMBASE (EXCERPTA MEDICA)  85-93/ISSUE
        (COPR. ESP BV/EM 1993)
 **FILE 72: Truncate EMTREE Codes (e.g. DC=C1.120?) for complete
  **retrieval.  The 9245 update has been added.
  File 350:Derwent World Patents Index
        1963-1990, EQUIVALENTS THRU DW=9247
 **FILE350:  Format  9  includes  the  expanded  patent  table.
Preformatted
  REPORTs are  available.  Type ?FMT350,  ?NEWS350, ?RATES350 for
more info.
  File 351:DERWENT WORLD PATENTS INDEX-LATEST
        1981+;DW=9251,UA=9239,UM=9208
 **FILE351:  Format  9  includes  the  expanded  patent  table.
Preformatted
  REPORTs are  available.  Type ?FMT351,  ?NEWS351, ?RATES351 for
more info.

      Set  Items  Description
      ---  -----  -----------
?s antivenin

      S1     591  ANTIVENIN
?s s1 and ( f(ab) or  fab fragment or f(ab)2)

            591  S1
              0  F(AB)
              4  FAB FRAGMENT
              0  F(AB)2
      S2      0  S1 AND ( F(AB) OR  FAB FRAGMENT OR F(AB)2)
?s s1 and ( f(ab) or fab(w)fragment or fab or fab2 )

            591  S1
              0  F(AB)
          19255  FAB
         132728  FRAGMENT
           2039  FAB(W)FRAGMENT
```

```
            78  FAB2
     S3      2  S1 AND ( F(AB) OR FAB(W)FRAGMENT OR FAB OR FAB2
)
?t s3/3/1,2


 3/3/1     (Item 1 from file: 155)
06089508   87063508
  Immunotherapy  in  the poisoned  patient. Overview of  present
applications
and future trends.
  Sullivan JB Jr
  Med Toxicol   Jan-Feb 1986,  1 (1) p47-60,  ISSN 0112-5966
Journal Code: MDT
  Languages: ENGLISH
  Document type: JOURNAL ARTICLE; REVIEW

 3/3/2     (Item 1 from file: 144)
  12276259   PASCAL No.: 92-0482170
  An  affinity  purified ovine  antivenom  for  the treatment  of
Vipera berus
envenoming
  SMITH D C; REDDI K R; LAING G; THEAKSTON R G D; LANDON J
  Therapeutic  Antibodies Inc.,  St. Bartholomew's  Hosp. Medical
school,
London, United Kingdom
  Journal: Toxicon : (Oxford),  1992, 30 (8) 865-871
  Language: English
?ds


Set     Items   Description









S1        591   ANTIVENIN
S2          0   S1 AND ( F(AB) OR  FAB FRAGMENT OR F(AB)2)
S3          2   S1 AND ( F(AB) OR FAB(W)FRAGMENT OR FAB OR FAB2 )

?s venom

     S4   23062  VENOM
?s fab or fab2

          19255  FAB
             78  FAB2
     S5   19302  FAB OR FAB2
?s s4 and s5

          23062  S4
          19302  S5
     S6      72  S4 AND S5
?rd

)))Duplicate detection is not supported for File 350.
)))Duplicate detection is not supported for File 351.
```

)))Records from unsupported files will be retained in the RD set.

...examined 50 records (50)
...completed examining records
     S7   40 RD (unique items)
?t s7/3/1-40

 7/3/1   (Item 1 from file: 155)
08306233 93016233
  Toxicity associated with the formation and clearance of immune complexes
between antitumour monoclonal antibodies and syngeneic anti-idiotypic
antibodies in mice.
  Pimm MV; Gribben SJ
  Cancer Research Campaign Laboratories, University of Nottingham, UK.
  J Cancer Res Clin Oncol (GERMANY) 1992, 119 (1) p41-5, ISSN 0171-5216
Journal Code: HLE
  Languages: ENGLISH
  Document type: JOURNAL ARTICLE

 7/3/2   (Item 2 from file: 155)
08259347 92397347
  An affinity purified ovine antivenom for the treatment of Vipera berus
envenoming.
  Smith DC; Reddi KR; Laing G; Theakston RG; Landon J
  Therapeutic Antibodies Inc., St. Bartholomew's Hospital Medical School,

London, U.K.
  Toxicon (ENGLAND) Aug 1992, 30 (8) p865-71, ISSN 0041-0101
Journal Code: VWT
  Languages: ENGLISH
  Document type: JOURNAL ARTICLE

 7/3/3   (Item 3 from file: 155)
08248192 92386192
  Limited proteolysis of human and rabbit immunoglobulins by snake venoms
produces Fab-like fragments.
  Assakura MT; Mandelbaum FR
  Servico de Bioquimica, Instituto Butantan, Sao Paulo, Brasil.
  Braz J Med Biol Res (BRAZIL) 1990, 23 (12) p1233-5, ISSN 0100-879X
Journal Code: BOF
  Languages: ENGLISH
  Document type: JOURNAL ARTICLE

 7/3/4   (Item 4 from file: 155)
07995510 92033510

Hepatic veno occlusive disease in a baboon model
anticoagulant
after allogeneic bone marrow transplantation.
Morio S; Ch H; Hirasawa A; Aotsuka N; Nakamura H; Asai T; Yoshida S; Ito
M
Second Department of Internal Medicine, School of Medicine, Chiba
University, Japan.
Bone Marrow Transplant (ENGLAND) Aug 1991, 8 (2) p147-9, ISSN
0268-3369 Journal Code: BON
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/5 (Item 5 from file: 155)
07885296 92023296
Neutralization of kinin-releasing enzymes of crotalid venoms by
monospecific and polyspecific antivenoms.
Bailey GS; al-Joufi A; Rawat S; Smith DC
Department of Chemistry and Biological Chemistry, University of Essex,
Colchester, U.K.
Toxicon 1991, 29 (6) p777-81, ISSN 0041-0101 Journal Code: VWT
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/6 (Item 6 from file: 155)
07804536 91323536
Crystallization and preliminary X-ray diffraction data of the Fab

fragment of a monoclonal antibody against apamin, a bee venom neurotoxin.
Devaux C; Defendini ML; Alzar PM; Abergel C; Granier C; Fontecilla-Camps
JC
Laboratoire de Biochimie, CNRS URA 1455, Faculte de Medecine-Nord,
Marseille, France.
FEBS Lett Jul 29 1991, 286 (1-2) p64-6, ISSN 0014-5793
Journal Code: EUH
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/7 (Item 7 from file: 155)
07552443 91071443
A new small myotoxin from the venom of the prairie rattlesnake (Crotalus
viridis viridis).
Griffin PR; Aird SD
California Institute of Technology, Division of Biology, Pasadena 91125.
FEBS Lett May 13 1990 274 (1-2) 43-7 ISSN 0014-5793

Journal Code: EUM
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/8 (Item 8 from file: 155)
07522655 91042655
Complement killing of human neuroblastoma cells: a cytotoxic monoclonal
antibody and its F(ab')2-cobra venom factor conjugate are equally
cytotoxic.
Juhl H; Petrella EC; Cheung NK; Bredehorst R; Vogel CW
Department of Biochemistry and Molecular Biology, Georgetown University,
Washington, DC 20007.
Mol Immunol Oct 1990, 27 (10) p957-64, ISSN 0161-5890
Journal Code: NGI
Contract/Grant No.: CA 35525; CA 01039
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/9 (Item 9 from file: 155)
07476500 90385500
Cleavage of immunoglobulins by moojeni protease A, from the venom of
Bothrops moojeni.
Assakura MT; Mandelbaum FR
Servico de Bioquimica, Instituto Butantan, Sao Paulo, Brasil.
Toxicon 1990, 28 (6) p734-6, ISSN 0041

-0101 Journal Code: VWT
Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/10 (Item 10 from file: 155)
07060610 89362610
Immunotoxicotherapy: present status and future trends.
Schermann JM; Terrien N; Urtizberea M; Pierson P; Denis H; Bourre JM
Inserm U.26, Hopital Fernand Widal, Paris, France.
J Toxicol Clin Toxicol 1989, 27 (1-2) p1-35, ISSN 0731-3810

Journal Code: KAN
Languages: ENGLISH
Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

7/3/11 (Item 11 from file: 155)
06989841 89291841
Molecular recognition in the activation of human blood coagulation factor
X.
Chattopadhyay A; Fair DS
Department of Biochemistry, University of Texas Health

75710.
J Biol Chem Jul 5 1989, 264 (19) p11035-43, ISSN 0021-9258
Journal Code: HIV
Contract/Grant No.: HL 39940
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/12 (Item 12 from file: 155)
06965705 89267705
Purification of F(ab')2 anti-snake venom by caprylic acid: a fast method
for obtaining IgG fragments with high neutralization activity, purity and
yield.
dos Santos MC; D'Imperio Lima MR; Furtado GC; Collette GM; Kipnis TL;
Dias da Silva W
Fundacao Ezequiel Dias, Universidade Federal de Minas Gerais, Brazil.
Toxicon 1989, 27 (3) p297-303, ISSN 0041-0101 Journal Code: VWT
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/13 (Item 13 from file: 155)
06869252 89171252
Neutralization of lethal potency and inhibition of enzymatic activity of
a phospholipase A2 neurotoxin, crotoxin, by non-precipitating antibodies
(Fab).
Chouet Y; Jiang MS; Radvanyi F; Cumby C; Bon C

Laboratoire des Venins, Institut Pasteur, Paris, France.
FEBS Lett Feb 13 1989, 244 (1) p167-73, ISSN 0014-5793
Journal Code: EUH
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/14 (Item 14 from file: 155)
06525042 88170042
Decay-accelerating factor protects human tumor cells from
complement-mediated cytotoxicity in vitro.
Cheung NK; Walter EI; Smith-Mensah WH; Ratnoff WD; Tykocinski ML; Medof
ME
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New
York 10021.
J Clin Invest Apr 1988, 81 (4) p1122-8, ISSN 0021-9738
Journal Code: HS7
Contract/Grant No.: CA-39200; AI-24220; AI-22530
Languages: ENGLISH

7/3/15 (Item 15 from file: 155)
06358393 88003393
Block of synaptic transmission in insect CNS by toxins from the venom of
the wasp Megascolia flavifrons (Fab.).
Piek T; Hue B; Mony L; Nakajima T; Pelhate M; Yasuhara T
Department of Pharmacology, University of Amsterdam, The Netherlands.
Comp Biochem Physiol [C] 1987, 87 (2) p287-95, ISSN 0742-8413
Journal Code: DNX
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/16 (Item 16 from file: 155)
06089508 87063508
Immunotherapy in the poisoned patient. Overview of present applications
and future trends.
Sullivan JB Jr
Med Toxicol Jan-Feb 1986, 1 (1) p47-60, ISSN 0112-5966
Journal Code: MDT
Languages: ENGLISH
Document type: JOURNAL ARTICLE; REVIEW

7/3/17 (Item 17 from file: 155)
06035955 87009955
Defining the role of complement in experimental pemphigus vulgaris in
mice.
Anhalt GJ; Till GO; Diaz LA; Labib RS; Patel HP; Eaglstein NF

J Immunol Nov 1 1986, 137 (9) p2835-40, ISSN 0022-1767
Journal Code: IFB
Contract/Grant No.: R23-AM32490; R23-AM32279; R01-AM32599; +
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/18 (Item 18 from file: 155)
05549020 85265020
Role of complement and the Fc portion of immunoglobulin G in immunity to
Venezuelan equine encephalomyelitis virus infection with
glycoprotein-specific monoclonal antibodies.
Mathews JH; Roehrig JT; Trent DW
J Virol Sep 1985, 55 (3) p594-600, ISSN 0022-538X Journal Code: KCV
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/19 (Item 19 from file: 155)
05534749 85150749

haematological changes
in the rabbit by methylprednisolone, F(ab')2 fragments and
rosmarinic acid.
  Bult H; Herman AG; Raspart M
  Br J Pharmacol Feb 1985, 84 (2) p317-27, ISt s7/3/9-42
SN 0007-1188
Journal Code: B0C
  Languages: ENGLISH
  Document type: JOURNAL ARTICLE

 7/3/20 (Item 20 from file: 155)
05410032 85026032
  Megascoliakinin, a bradykinin-like compound in the venom of
Megascolia
flavifrons Fab. (Hymenoptera: Scoliidae).
  Piek T; Mantel P; Van Ginkel CJ
  Comp Biochem Physiol [C] 1984, 78 (2) p473-4, ISSN
0742-8413
Journal Code: DNX
  Languages: ENGLISH
  Document type: JOURNAL ARTICLE

 7/3/21 (Item 21 from file: 155)
04706845 82249845
  Neurotoxin-specific immunoglobulins accelerate
dissociation of the
neurotoxin-acetylcholine receptor complex.
  Boulain JC; Menez A
  Science Aug 20 1982, 217 (4561) p732-3, ISSN 0036-8075
Journal Code: UJ7
  Languages: ENGLISH
  Document type: JOURNAL ARTICLE

 7/3/22 (Item 22 from file: 155)
04228391 81056391
  Inhibition of biological activity of mouse beta-nerve growth
factor by
monoclonal antibody.
  Warren SL; Fanger M; Neet KE
  Science Nov 21 1980, 210 (4472) p910-2, ISSN 0036-8075
Journal Code: UJ7
  Contract/Grant No.: AI10148; CA27915
  Languages: ENGLISH
  Document type: JOURNAL ARTICLE

 7/3/23 (Item 23 from file: 155)
04183515 81011516
  Immunopharmacological approach to Forssman shock.
  Nagai M; Kumimoto Y; Koda A
  Microbiol Immunol 1980, 24 (7) p649-55, Journal Code: MX7
  Languages: ENGLISH
  Document type: JOURNAL ARTICLE

04363695 80174695
Immune retention: immunological requirements for maintaining an easily
degradable antigen in vivo.
Tew JG; Mandel TE; Miller GA
Aust J Exp Biol Med Sci Aug 1979, 57 (4) p401-14, ISSN 0004-945X
Journal Code: 9FW
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/25 (Item 25 from file: 155)
03671494 79248494
Immunological studies on pancreatic phospholipase A2. Antigenic
characterization of the NH2-terminal region.
Meijer W; Meddens MJ; Dijkman R; Slotboom AJ; de Haas GH
J Biol Chem Dec 10 1978, 253 (23) p8564-9, ISSN 0021-9258
Journal Code: HIV
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/26 (Item 26 from file: 155)
02909946 76090946
Guinea-pig nephrotoxic nephritis. I. The role of complement and
polymorphonuclear leucocytes and the effect of antibody subclass and
fragments in the heterologous phase.
Simpson IJ; Amos N; Evans DJ; Thorsen NM; Peters DK
Clin Exp Immunol Mar 1975, 19 (3) p499-511, ISSN 0009-9104
Journal Code: DD7

Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/27 (Item 1 from file: 55)
9149815 BIOSIS Number: 93134315
NOVEL QUATERNARY AMMONIUM SALT-CONTAINING POLYAMINES FROM THE
AGELENOPSIS-APERTA FUNNEL-WEB SPIDER
JASYS V J; KELBAUGH P R; MASON D M; PHILLIPS D; ROSNACK K J;
FORMAN J T;
SACCOMANO N A; STACH J S; VOLKMANN R A
CENTRAL RESEARCH DIVISION, PFIZER INC., GROTON, CONN. 06340.
J ORG CHEM 57 (6). 1992. 1814-1820. CODEN: JOCEA
Full Journal Title: Journal of Organic Chemistry
Language: ENGLISH

7/3/28 (Item 2 from file: 55)
9138809 BIOSIS Number: 93123809
CORRECTION OF BA 92098484. CRYSTALLIZATION AND PRELIMINARY X-RAY
DIFFRACTION DATA OF THE FAB FRAGMENT OF A MONOCLONAL ANTIBODY AGAINST

PEDRO M.
ALZAR. ERRATUM PUBLISHED IN FEBS FED EUR BIOCHEM SOC LETT VOL. 292. ISS.
1-2. 1991. P. 307
  DEVAUX C; DEFENDINI M-L; ALZARI P M; ABERSEL C; GRANIER C; FONTECILLA-CAMPS J C
  LAB. BIOCHEM., FAC. MED.-NORD, BOULEVARD PIERRE DRAMARD, 13326 MARSEILLE
CEDEX 15, FR.
  FEBS (FED EUR BIOCHEM SOC) LETT 286 (1/2). 1991. 64-66.
CODEN: FEBLB
  Full Journal Title: FEBS (Federation of European Biochemical Societies)
Letters
  Language: ENGLISH

 7/3/29 (Item 3 from file: 55)
8559708 BIOSIS Number: 92023708
  A SANDWICH ENZYME-IMMUNOASSAY FOR DETECTING SNAKE VENOM
  GE B; YU H; WANG J; XU Y
  SHANGHAI INST. BIOCHEMISTRY, ACADEMIA SINICA.
  ZOOL RES 12 (1). 1991. 79-83. CODEN: DOYAD
  Full Journal Title: Zoological Research
  Language: CHINESE

 7/3/30 (Item 4 from file: 55)
7749725 BIOSIS Number: 90117725
  ISOLATION STRUCTURE ELUCIDATION AND SYNTHESIS OF NOVEL HYDROXYLAMINE-CONTAINING POLYAMINES FROM THE VENOM OF THE AGELENOPSIS-APERTA SPIDER
  JASYS V J; KELBAUGH P R; NASON D M; PHILLIPS D; ROSNACK K J; SACCOMANO N

A; STROH J G; VOLKMANN R A
  CENTRAL RES., PFIZER INC., GROTON, CONN. 06340.
  J AM CHEM SOC 112 (18). 1990. 6696-6704. CODEN: JACSA
  Full Journal Title: Journal of the American Chemical Society
  Language: ENGLISH

 7/3/31 (Item 5 from file: 55)
7114115 BIOSIS Number: 00038860
  USING AFFINITY CHROMATOGRAPHY TO ISOLATE ALPHA LATROTOXIN FROM THE VENOM
OF THE SPIDER LATRODECTUS-TREDECIMGUTTATUS
  DALIMOV B Z; KASYMOV SH K; SALIKHOV SH I
  A.S. SADYKOV INST. BIOORG. CHEM., ACAD. SCI. UZB. SSR, TASHKENT, USSR.
  KHIM PRIR SOEDIN (TASHK) 0 (5). 1990. 679-682. CODEN: KPSUA
  Full Journal Title: Khimiya Prirodnykh Soedinenii (Tashkent)
  Language: RUSSIAN

 7/3/32 (Item 6 from file: 55)
7071659 BIOSIS Number: 87132130
  PURIFICATION OF FAB'-2 ANTI-SNAKE VENOM BY CAPRYLIC ACID A FAST

FOR OBTAINING IGG FRAGMENTS WITH HIGH NEUTRALIZATION ACTIVITY PURITY AND
YIELD
SANTOS M C D; LIMA M R D; FURTADO G C; COLLETTO G M D D; KIPNIS T L;
SILVA W D D
DEP. IMMUNOL., INST. CIENCIAS BIOMED., UNIV. SAO PAULO, BRAZIL.

TOXICON 27 (3). 1989. 297-304. CODEN: TOXIA
Full Journal Title: Toxicon
Language: ENGLISH

7/3/33 (Item 1 from file: 144)
10226038 PASCAL No.: 92-0431941
Analysis of a mastoparan P isolated from the hornet (Vespa Basalis) venom
by fast atom bombardement mass spectrometry with B/E linked scan
YONG-CHIEN LING; BANG-JI LIU; JIRN-MEHNG LO; CHEW-LANG HO
National Tsing Hua univ., dep. chemistry, Hsinchu 300, Taiwan
Journal: Spectroscopy letters, 1992, 25 (2) 245-255
Language: English

7/3/34 (Item 2 from file: 144)
09555774 PASCAL No.: 91-0246201
Structure and biological activities of a new mastoparan isolated from the
venom of the hornet Vespa basalis
CHEWN-LANG HC; LING-LING HWANG
Acad. sinica, inst. biological chemistry, Taipei 10798, Taiwan
Journal: Biochemical journal : (London. 1984), 1991, 274 (2) 453-456
Language: English

7/3/35 (Item 3 from file: 144)
09114143 PASCAL No.: 90-0282524
Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms:
evidence for a family of platelet-aggregation inhibitors
DENNIS M S; HENZEL W J; PITTI R M; LIPARI M T; NAPIER M A; DEISHER T A;
BUNTING S; LAZARUS R A
Genentech, Inc., dep. biomolecular chemistry, South San Francisco CA
94080, USA
Journal: Proceedings of the National Academy of Sciences of the United
States of America (1935), 1990, 87 (7) 2471-2475
Language: English

7/3/36 (Item 1 from file: 72)
8528645 EMBASE No: 92204527
Monoclonal antibodies to toxin II from the scorpion Androctonus australis

neutralizing
capacities
Yahi N.; Devaux C.; Mancuelle P.; Defendini M.-L.; Granier C.
CNRS URA 1455, Laboratoire de Biochimie, Faculte de Medecine Secteur
Nord, Boulevard Pierre Dramard, 13326 Marseille Cedex 15 France
TOXICON (United Kingdom) , 1992, 30/7 (723-731) CODEN: TOXIA ISSN:
0041-0101 ADONIS ORDER NUMBER: 004101019200075S
LANGUAGES: English SUMMARY LANGUAGES: English

7/3/37 (Item 2 from file: 72)
8343871 EMBASE No: 92020617
Neutralization of kinin-releasing enzymes from viperid venoms by
antivenom IgG fragments
Al-Joufi A.; Bailey G.S.; Reddi K.; Smith D.C.
Department of Chemistry and Biological Chemistry, University of Essex,
Colchester, Essex CO4 3SQ United Kingdom
TOXICON (United Kingdom) , 1991, 29/12 (1509-1511) CODEN: TOXIA ISSN:
0041-0101 ADONIS ORDER NUMBER: 004101019200023Z
LANGUAGES: English SUMMARY LANGUAGES: English

7/3/38 (Item 3 from file: 72)
8310262 EMBASE No: 91340983
Erratum: Crystallization and preliminary X-ray diffraction data of the
Fab fragment of a monoclonal antibody against apamin, a bee venom
neurotoxin (FEBS Letters (1991) 285 (64-66))

Devaux C.; Defendini M.-L.; Alzar P.M.; Abergel C.; Granier C.;
Fontecilla-Camps J.C.
FEBS LETT. (Netherlands) , 1991, 292/1-2 (307) CODEN: FEBLA ISSN:
0014-5793 ADONIS ORDER NUMBER: 001457939101451L
LANGUAGES: English

7/3/39 (Item 4 from file: 72)
8212121 EMBASE No: 07049774
Use of antibodies specific to defined regions of scorpion alpha-toxin to
study its interaction with its receptor site on the sodium channel
Ayeb E.M.; Bahraoui E.M.; Granier C.; Rochat H.
INSERM U172 and CNRS UA 553, Laboratoire de Biochimie, Faculte de
Medecine Secteur Nord, 13326 Marseille Cedex 15 FRANCE
BIOCHEMISTRY (USA) , 1990, 29/27 (6671-6678) CODEN: BICHA
LANGUAGES: ENGLISH

7/3/40 (Item 1 from file: 351)

028442348 WPI Acc No: 90-229348/44
XRPX Acc No: C90-142975
New poly-amine(s) and polypeptide(s) from spider venom - are excitatory
amino acid neuro-transmitter antagonists and calcium channel blockers
Patent Assignee: (NATU-) NATURAL PROD SCI INC; (PFIZ) PFIZER INC

Author (Inventor): SACCOMANO N A; VOLKMANN R A
Patent Family:

CC Number	Kind	Date	Week	
EP 395357	A	901031	9044	(Basic)
PT 93876	A	901120	9050	
AU 9054535	A	901108	9101	
NO 9001881	A	901029	9101	
CA 2015505	A	901028	9104	
FI 9002139	A	901029	9107	
JP 3014551	A	910122	9110	
HU T55415	T	910528	9127	
CN 1047078	A	901121	9131	
ZA 9003229	A	911224	9205	
DD 293959	A	910919	9208	
DD 298412	A5	920220	9229	
CS 9002157	A2	920219	9237	

Priority Data (CC No Date): US 345131 (890428)
Applications (CC,No,Date): CS 902157 (900428); EP 90304397 (900424); JP
90115704 (900501); ZA 903229 (900427); DD 343278 (900805)
?

7/3/9 (Item 9 from file: 155)
07478500 90385500

Cleavage of immunoglobulins by neojeni protease A, from the venom of
Bothrops neojeni.
Assakura MT; Mandelbaum FR
Servico de Bioquimica, Instituto Butantan, Sao Paulo, Brasil.
Toxicon 1990, 28 (5) p734-6, ISSN 0041-0101 Journal Code: VWT
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/10 (Item 10 from file: 155)
07060610 89352610
Immunotoxicotherapy: present status and future trends.
Scherrmann JM; Terrien N; Urtizberea M; Pierson P; Denis M; Bourre JM
Inserm U.26, Hopital Fernand Widal, Paris, France.
J Toxicol Clin Toxicol 1989, 27 (1-2) p1-35, ISSN 0731-3810

Journal Code: MAN
Languages: ENGLISH
Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

7/3/11 (Item 11 from file: 155)
06939841 89291841
Molecular recognition in the activation of human blood coagulation factor X.
Chattopadhyay A; Fair DS
Department of Biochemistry, University of Texas Health Center, Tyler 75710.
J Biol Chem Jul 5 1989, 264 (19) p11035-43, ISSN 0021-9258
Journal Code: HIV
Contract/Grant No.: HL 39242
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/12 (Item 12 from file: 155)
06965705 89267705
Purification of F(ab')2 anti-snake venom by caprylic acid: a fast method for obtaining IgG fragments with high neutralization activity, purity and yield.
dos Santos MC; D'Imperio Lima MR; Furtado GC; Colletto GM; Kipnis TL; Dias da Silva W
Fundacao Ezequiel Dias, Universidade Federal de Minas Gerais, Brazil.
Toxicon 1989, 27 (3) p297-303, ISSN 0041-0101 Journal Code: VWT
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/13 (Item 13 from file: 155)
06869252 89171252
Neutralization of lethal potency and inhibition of enzymatic activity of a phospholipase A2 neurotoxin, crotoxin, by non-precipitating antibodies (Fab).
Choumet V; Jiang MS; Radvanyi F; Ownby C; Bon C
Laboratoire des Venins, Institut Pasteur, Paris, France.
FEBS Lett Feb 13 1989, 244 (1) p167-73, ISSN 0014-5793
Journal Code: EUH
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/14 (Item 14 from file: 155)
06525042 88170042
Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro.
Cheung NK; Walter EI; Smith-Mensah WH; Ratnoff WD; Tykocinski ML; Medof ME

Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New
York 10021.
J Clin Invest Apr 1988, 81 (4) p1122-8, ISSN 0021-9738
Journal Code: HS7
Contract/Grant No.: CA-39320; AI-24220; AI-23598
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/15 (Item 15 from file: 155)
06358393 88003393
Block of synaptic transmission in insect CNS by toxins from the venom of
the wasp Megascolia flavifrons (Fab.).
Piek T; Hue B; Mony L; Nakajima T; Pelhate M; Yasuhara T
Department of Pharmacology, University of Amsterdam, The Netherlands.
Comp Biochem Physiol [C] 1987, 87 (2) p287-95, ISSN 0742-8413
Journal Code: DNX
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/16 (Item 16 from file: 155)
06089508 87063508
Immunotherapy in the poisoned patient. Overview of present applications
and future trends.
Sullivan JB Jr
Med Toxicol Jan-Feb 1986, 1 (1) p47-60, ISSN 0112-5966
Journal Code: MDT
Languages: ENGLISH

Document type: JOURNAL ARTICLE; REVIEW

7/3/17 (Item 17 from file: 155)
06035955 87009955
Defining the role of complement in experimental pemphigus vulgaris in
mice.
Anhalt GJ; Till GO; Diaz LA; Labib RS; Patel HP; Eaglstein NF
J Immunol Nov 1 1986, 137 (9) p2835-40, ISSN 0022-1767
Journal Code: IFB
Contract/Grant No.: R23-AM32490; R23-AM32079; R01-AM32599; +
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/18 (Item 18 from file: 155)
05649020 85265020
Role of complement and the Fc portion of immunoglobulin G in immunity to
Venezuelan equine encephalomyelitis virus infection with
glycoprotein-specific monoclonal antibodies.

J Virol Sep 1985, 55 (3) p594-600, ISSN 0022-538X Journal Code: KCV
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/19 (Item 19 from file: 155)
05534749 85150749
Modification of endotoxin-induced haemodynamic and haematological changes
in the rabbit by methylprednisolone, F(ab')2 fragments and rosmarinic acid.
Bult H; Herman AG; Rampart M
Br J Pharmacol Feb 1985, 84 (2) p317-27, ISSN 0007-1188
Journal Code: B00
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/20 (Item 20 from file: 155)
05410032 85026032
Megascoliakinin, a bradykinin-like compound in the venom of Megascolia
flavifrons Fab. (Hymenoptera: Scoliidae).
Piek T; Mantel P; Van Ginkel CJ
Comp Biochem Physiol [C] 1984, 78 (2) p473-4, ISSN 0742-8413
Journal Code: DNX
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/21 (Item 21 from file: 155)
04706845 82249845
Neurotoxin-specific immunoglobulins accelerate dissociation of the
neurotoxin-acetylcholine receptor complex.
Boulain JC; Menez A
Science Aug 20 1982, 217 (4561) p732-3, ISSN 0036-8075
Journal Code: UJ7
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/22 (Item 22 from file: 155)
04228391 81056391
Inhibition of biological activity of mouse beta-nerve growth factor by
monoclonal antibody.
Warren SL; Fanger M; Neet KE
Science Nov 21 1980, 210 (4472) p910-2, ISSN 0036-8075
Journal Code: UJ7
Contract/Grant No.: AI10148; CA27915
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/23 (Item 23 from file: 155)
04103516 81011516

Immunopharmacological approach to Forssman shock.
Nagai H; Mamiuchi Y; Kodo O
Microbiol Immunol 1980, 24 (7) p649-55, Journal Code: MX7
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/24 (Item 24 from file: 155)
04853605 80174695
Immune retention: immunological requirements for maintaining an easily
degradable antigen in vivo.
Tew JG; Mandel TE; Miller GA
Aust J Exp Biol Med Sci Aug 1979, 57 (4) p401-14, ISSN 0004-945X
Journal Code: 9FW
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/25 (Item 25 from file: 155)
03671494 79048494
Immunological studies on pancreatic phospholipase A2. Antigenic
characterization of the NH2-terminal region.
Meijer H; Meddens MJ; Dijkman R; Slotboom AJ; de Haas GH
J Biol Chem Dec 10 1978, 253 (23) p8564-9, ISSN 0021-9258
Journal Code: HIV
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/26 (Item 26 from file: 155)
02909946 78090946
Guinea-pig nephrotoxic nephritis. I. The role of complement and
polymorphonuclear leucocytes and the effect of antibody subclass and
fragments in the heterologous phase.
Simpson IJ; Azzo N; Evans DJ; Thomson NM; Peters DK
Clin Exp Immunol Mar 1975, 19 (3) p499-511, ISSN 0009-9104
Journal Code: DD7
Languages: ENGLISH
Document type: JOURNAL ARTICLE

7/3/27 (Item 1 from file: 55)
9149315 DIALOG Number: 93134815
NOVEL QUATERNARY AMMONIUM SALT-CONTAINING POLYAMINES FROM THE
ABELSONPOIS APERTA FUNNEL-WEB SPIDER
JASYS V J; KELBAUGH P R; MASON D M; PHILLIPS D; ROSNACK K J;
FORMAN J T;
BRASSMANS N A; STROH J G; VOLKMANN R A
CENTRAL RESEARCH DIVISION, PFIZER INC., GROTON, CONN. 06340.
J ORG CHEM 57 (6). 1992. 1814-1820. CODEN: JOCE
Full Journal Title: Journal of Organic Chemistry
Language: ENGLISH

7/3/29 (Item 2 from file: 55)
9138809 BIOSIS Number: 92138809
CORRECTION OF BA 92088484. CRYSTALLIZATION AND PRELIMINARY X-RAY
DIFFRACTION DATA OF THE FAB FRAGMENT OF A MONOCLONAL ANTIBODY AGAINST
APAMIN A BEE VENOM NEUROTOXIN. CORRECTION OF AUTHOR NAME FROM PEDRO M.
ALZARI. ERRATUM PUBLISHED IN FEBS FED EUR BIOCHEM SOC LETT VOL. 292. ISS.
1-2. 1991. P. 307
DEVAUX C; DEFENDINI M-L; ALZARI P M; ABERGEL C; GRANIER C; FONTECILLA-CAMPS J C
LAB. BIOCHEM., FAC. MED.-NORD, BOULEVARD PIERRE DRAMARD, 13326 MARSEILLE
CEDEX 15, FR.
FEBS (FED EUR BIOCHEM SOC) LETT 286 (1/2). 1991. 64-65.
CODEN: FEBLA
Full Journal Title: FEBS (Federation of European Biochemical Societies)
Letters
Language: ENGLISH

7/3/29 (Item 3 from file: 55)
3558708 BIOSIS Number: 92023708
A SANDWICH ENZYME-IMMUNOASSAY FOR DETECTING SNAKE VENOM
SE B; YU M; WANG J; XU Y
SHANGHAI INST. BIOCHEMISTRY, ACADEMIA SINICA.
ZOOL RES 12 (1). 1991. 79-82. CODEN: DOYAD
Full Journal Title: Zoological Research
Language: CHINESE

7/3/30 (Item 4 from file: 55)
7749725 BIOSIS Number: 90117725
ISOLATION STRUCTURE ELUCIDATION AND SYNTHESIS OF NOVEL HYDROXYLAMINE-CONTAINING POLYAMINES FROM THE VENOM OF THE ASELENOPSIS-APERTA SPIDER
JASYS V J; KELBAUGH P R; NASON D M; PHILLIPS D; ROSNACK K J; SPOONHAND N
A; STROH J G; VOLKMANN R A
CENTRAL RES., PFIZER INC., GROTON, CONN. 06340.
J AM CHEM SOC 112 (18). 1990. 6696-6704. CODEN: JACSA
Full Journal Title: Journal of the American Chemical Society
Language: ENGLISH

7/3/31 (Item 5 from file: 55)
7116115 BIOSIS Number: 90028060
USING AFFINITY CHROMATOGRAPHY TO ISOLATE ALPHA LATROTOXIN FROM THE VENOM
OF THE SPIDER LATRODECTUS-TREDECIMGUTTATUS
BALINOV B Z; VASYNOV CH K; GALIKUOV CH I
A.S. SADYKOV INST. BIOORG. CHEM., ACAD. SCI. UZB. SSR, TASHKENT, USSR.
[illegible]

Full Journal Title: Khimiya Prirodnykh Soedinenii (Tashkent)
Language: RUSSIAN

7/3/32 (Item 6 from file: 55)
7071659 BIOSIS Number: 87132150
PURIFICATION OF FAB'-2 ANTI-SNAKE VENOM BY CAPRYLIC ACID A FAST METHOD
FOR OBTAINING IGG FRAGMENTS WITH HIGH NEUTRALIZATION ACTIVITY PURITY AND
YIELD
SANTOS M C D; LIMA M R D; FURTADO G C; COLLETTO G M D D; KIPNIS T L;
SILVA W D D
DEP. IMMUNOL., INST. CIENCIAS BIOMED., UNIV. SAO PAULO, BRAZIL.

TOXICON 27 (3). 1989. 297-304. CODEN: TOXIA
Full Journal Title: Toxicon
Language: ENGLISH

7/3/33 (Item 1 from file: 144)
10226038 PASCAL No.: 92-0431941
Analysis of a bastoparan B isolated from the hornet (Vespa Basalis) venom
by fast atom bombardement mass spectrometry with B/E linked scan
YONG-CHIEN LING; BANG-JI LIU; JIUN-MEHNG LO; CHEW-LANG KO
National Tsing Hua univ., dep. chemistry, Hsinchu 300, Taiwan
Journal: Spectroscopy letters, 1992, 25 (2) 245-255
Language: English

7/3/34 (Item 2 from file: 144)
09555774 PASCAL No.: 91-0346201
Structure and biological activities of a new bastoparan isolated from the
venom of the hornet Vespa basalis
CHEW-LANG KO; LING-LING HUANG
Acad. sinica, inst. biological chemistry, Taipei 10798, Taiwan
Journal: Biochemical journal : (London. 1984), 1991, 274 (2) 453-456
Language: English

7/3/35 (Item 3 from file: 144)
03114143 PASCAL No.: 90-0282524
Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms:
evidence for a family of platelet-aggregation inhibitors
DENNIS M S; HENZEL W J; PITTI R M; LIPARI M T; NAPIER M A;
DEISHER T A;
BUNTING S; LAZARUS R A
Genentech, Inc., dep. biomolecular chemistry, South San Francisco CA
94080, USA
Journal: Proceedings of the National Academy of Sciences of the United

Language: English

7/3/25 (Item 1 from file: 72)
0520545 EMBASE No: 92204527
Monoclonal antibodies to toxin II from the scorpion Androctonus australis
Hector: Further characterization of epitope specificities and neutralizing
capacities
Yahi N.; Devaux C.; Mansuelle P.; Defendini M.-L.; Granier C.
CNRS URA 1455, Laboratoire de Biochimie, Faculte de Medecine Secteur
Nord, Boulevard Pierre Dramard, 13326 Marseille Cedex 15 France
TOXICON (United Kingdom) , 1992, 30/7 (723-731) CODEN: TOXIA ISSN:
0041-0101 ADONIS ORDER NUMBER: 004101019200075Z
LANGUAGES: English SUMMARY LANGUAGES: English

7/3/27 (Item 2 from file: 72)
0342871 EMBASE No: 92020617
Neutralization of kinin-releasing enzymes from viperid venoms by
antivenom IgG fragments
Al-Joufi A.; Bailey G.S.; Reddi K.; Smith D.C.
Department of Chemistry and Biological Chemistry, University of Essex,
Colchester, Essex CO4 3SQ United Kingdom
TOXICON (United Kingdom) , 1991, 29/12 (1509-1511) CODEN: TOXIA ISSN:
0041-0101 ADONIS ORDER NUMBER: 004101019200099I
LANGUAGES: English SUMMARY LANGUAGES: English

7/3/29 (Item 3 from file: 72)
0312262 EMBASE No: 91340920
Erratum: Crystallization and preliminary X-ray diffraction data of the
Fab fragment of a monoclonal antibody against apamin, a bee venom
neurotoxin (FEBS Letters (1991) 285 (54-56))
Devaux C.; Defendini M.-L.; Alzari P.M.; Abergel C.; Granier C.;
Fontecilla-Camps J.C.
FEBS LETT. (Netherlands) , 1991, 292/1-2 (307) CODEN: FEBLA ISSN:
0014-5793 ADONIS ORDER NUMBER: 001457939101451L
LANGUAGES: English

7/3/39 (Item 4 from file: 72)
0313121 EMBASE No: 07040774
Use of antibodies specific to defined regions of scorpion alpha-toxin to
study its interaction with its receptor site on the sodium channel

INSERM U172 and CNRS UA 553, Laboratoire de Biochimie, Faculte de
Medecine Secteur Nord, 13326 Marseille Cedex 15 FRANCE
BIOCHEMISTRY (USA) , 1986, 25/21 (6671-6678) CODEN: BICHA
LANGUAGES: ENGLISH

7/3/40 (Item 1 from file: 351)
008442348 WPI Acc No: 90-329348/44
XRAM Acc No: C90-142975
New poly-amine(s) and polypeptide(s) from spider venom - are excitatory
amino acid neuro-transmitter antagonists and calcium channel blockers
Patent Assignee: (NATU-) NATURAL PROD SCI INC; (PFIZ) PFIZER INC

Author (Inventor): SACCOMANO N A; VOLKMANN R A
Patent Family:

CC Number	Kind	Date	Week	
EP 395357	A	901031	9044	(Basic)
PT 93876	A	901120	9050	
AU 9054535	A	901108	9101	
NO 9001881	A	901029	9101	
CA 2015505	A	901028	9104	
FI 9002139	A	901029	9107	
JP 3014551	A	910123	9110	
HU T55415	T	910528	9127	
CN 1047078	A	901121	9131	
ZA 9003229	A	911224	9205	
DD 293959	A	910919	9208	
DD 298412	A5	920220	9229	
CS 9002157	A2	920219	9237	

Priority Data (CC No Date): US 346181 (890428)

Applications (CC,No,Date): CS 902157 (900428); EP 90304397 (900424); JP
90115704 (900501); ZA 903229 (900427); DD 343270 (900806)
?ds

Set	Items	Description
S1	591	ANTIVENIN
S2	0	S1 AND (F(AB) OR FAB FRAGMENT OR F(AB)2)
S3	2	S1 AND (F(AB) OR FAB(W)FRAGMENT OR FAB OR FAB2)
S4	23062	VENOM
S5	19302	FAB OR FAB2
S6	72	S4 AND S5
S7	40	RD (unique items)

?s s5 and polyacrylamide

	19302	S5
	146486	POLYACRYLAMIDE
S8	586	S5 AND POLYACRYLAMIDE

? s s8 and (pepsin or papain)

```
          586  S8
        15000  PEPSIN
        10290  PAPAIN
     S9     92  S8 AND (PEPSIN OR PAPAIN)
?rd

)))Duplicate detection is not supported for File 350.
)))Duplicate detection is not supported for File 351.

)))Records from unsupported files will be retained in the RD set.

...examined 50 records  (50)
...completed examining records
     S10     75  RD (unique items)
?t s10/3/1-75


 10/3/1     (Item 1 from file: 155)
00177636   92315636
  Thiol groups and other chemical characteristics of rat
monoclonal
immunoglobulin A.
  Gertler S; Young NM
  Institute for Biological Sciences, National Research Council
of Canada,
Ottawa, Ontario.
  Comp Biochem Physiol [B] (ENGLAND)    Jun 1992,   102 (2)
p377-81,  ISSN
0305-0491   Journal Code: DNV
  Languages: ENGLISH
  Document type: JOURNAL ARTICLE


 10/3/2     (Item 2 from file: 155)
00000766   92218766
  Single-step purification of F(ab')2 fragments of mouse
monoclonal
antibodies (immunoglobulins G1) by hydrophobic interaction high
performance
liquid chromatography using TSKgel Phenyl-5PW.
  Morimoto K; Inouye K
  Biotechnology Research Laboratories, TOSOH Corporation,
Kanagawa, Japan.
  J Biochem Biophys Methods (NETHERLANDS)    Mar 1992,  24 (1-2)
p107-17,
ISSN 0165-022X   Journal Code: H94
  Languages: ENGLISH
  Document type: JOURNAL ARTICLE

 10/3/3     (Item 3 from file: 155)
07849323   91368323
  Dose-dependent reversal of acute murine colchicine
poisoning by goat
colchicine-specific Fab fragments.
```

Scherrmann
JM
  Institut National de la Sante et de la Recherche Medicale U26, Hopital
Fernand Widal, Paris, France.
  Toxicology 1991, 66 (2) p121-32, ISSN 0300-483X Journal Code: VVR
  Languages: ENGLISH
  Document type: JOURNAL ARTICLE

 10/3/4 (Item 4 from file: 155)
07823692 91342692
  The Fab/c fragment of IgG produced by cleavage at cyanocysteine residues.
  Wines BD; Easterbrook-Smith SB
  Department of Biochemistry, University of Sydney, N.S.W., Australia.
  Mol Immunol Aug 1991, 28 (8) p855-63, ISSN 0161-5890 Journal Code:
NBI
  Languages: ENGLISH
  Document type: JOURNAL ARTICLE

 10/3/5 (Item 5 from file: 155)
07821680 91340680
  Vasoactive intestinal peptide hydrolysis by antibody light chains.
  Mei S; Mody B; Ehlund SM; Paul S
  Department of Pharmacology, University of Nebraska Medical Center, Omaha
68198-6200.
  J Biol Chem Aug 25 1991, 266 (24) p15571-4, ISSN 0021-9258

Journal Code: HIV
  Contract/Grant No.: HL40348; HL44123; HL22217
  Languages: ENGLISH
  Document type: JOURNAL ARTICLE

 10/3/6 (Item 6 from file: 155)
07691547 91210547
  Proteolytic digestion of mouse IgE.
  Maba S; Misonoff J
  Department of Biology, Brandeis University, Waltham, MA 02254.
  J Immunol Methods Apr 8 1991, 138 (1) p15-22, ISSN 0022-1759
Journal Code: ISE
  Contract/Grant No.: AI-22068
  Languages: ENGLISH
  Document type: JOURNAL ARTICLE

 10/3/7 (Item 7 from file: 155)
07571709 91190709
  The specificity of the IgG receptor purified from human neutrophils.

Department of Pathology, University of Dundee, Ninewells Hospital Medical
School, Scotland, U.K.
Biochem J Nov 15 1990, 272 (1) p159-65, ISSN 0264-6021
Journal Code: 9YO
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/8 (Item 8 from file: 155)
07569635 91088635
Preparation and crystallization of a human immunodeficiency virus p24-Fab
complex.
Prongay AJ; Smith TJ; Rossmann MG; Ehrlich LS; Carter CA; McClure J
Department of Biological Sciences, Purdue University, West Lafayette, IN
47907.
Proc Natl Acad Sci U S A Dec 1990, 87 (24) p9980-4, ISSN 0027-8424
Journal Code: PV3
Contract/Grant No.: AI25993; AI27310
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/9 (Item 9 from file: 155)
07552858 91071858
Purification and characterization of an outer membrane protein adhesin
from Haemophilus parainfluenzae HP-28.
Lai CH; Bloomquist C; Liljemark WF
Department of Diagnostic School of Dentistry, University of

Minnesota,
Minneapolis 55455.
Infect Immun Dec 1990, 58 (12) p3833-9, ISSN 0019-9567
Journal Code: G07
Contract/Grant No.: R37-DE04614
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/10 (Item 10 from file: 155)
07400795 90307795
Characterization of a maternal type VI collagen in Xenopus embryos
suggests a role for collagen in gastrulation.
Otte AP; Roy D; Siemerink M; Koster CH; Hochstenbach F; Timmermans A;
Durston AJ
Hubrecht Laboratory, Netherlands Institute for Developmental Biology,
Utrecht.
J Cell Biol Jul 1990, 111 (1) p271-8, ISSN 0021-9525
Journal Code:

Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/11 (Item 11 from file: 155)
07349288 90256288
A proteolytic enzyme secreted by Proteus mirabilis degrades
immunoglobulins of the immunoglobulin A1 (IgA1), IgA2, and IgG isotypes.
Loomes LM; Senior BW; Kerr MA
Department of Pathology, Dundee University Medical School, Ninewells
Hospital, Scotland.
Infect Immun Jun 1990, 58 (6) p1979-85, ISSN 0019-9567
Journal Code: G07
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/12 (Item 12 from file: 155)
07345988 90252988
Adaptation of fluorescence polarization immunoassay to the assay of
macromolecules.
Urios P; Cittanova N
Departement de Biochimie, U.F.R. Biomedicale des Saints-Peres, Paris,
France.
Anal Biochem Mar 1990, 185 (2) p308-12, ISSN 0003-2697
Journal Code: 4NK
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/13 (Item 13 from file: 155)
07062848 89364848
Immunochemical studies of a murine polyreactive IgG2b autoantibody with
rheumatoid factor activity.
Fernandez PA; Ternynck T; Avrameas S
Departement d'Immunologie, Institut Pasteur, Paris, France.
Mol Immunol Jun 1989, 26 (6) p539-49, ISSN 0161-5890
Journal Code:
NG1
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/14 (Item 14 from file: 155)
07025206 89327206
Physical, enzymatic, and contractile properties of brain myosin with
anti-brain myosin Fab fragment bound on its tail.
Matsumura S; Ohmori K; Chiba T; Kumon A
Department of Biochemistry, Saga Medical School.
J Biochem (Tokyo) May 1989, 105 (5) p803-12, ISSN 0021-924X

Journal Code: HIF
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/15 (Item 15 from file: 155)
06965705 89267705
Purification of F(ab')2 anti-snake venom by caprylic acid: a fast method
for obtaining IgG fragments with high neutralization activity, purity and
yield.
dos Santos MC; D'Imperio Lima MR; Furtado GC; Colletto GM; Kipnis TL;
Dias da Silva W
Fundacao Ezequiel Dias, Universidade Federal de Minas Gerais, Brazil.
Toxicon 1989, 27 (3) p297-303, ISSN 0041-0101 Journal Code: VWT
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/16 (Item 16 from file: 155)
06947897 89249897
Sensitive enzyme immunoassay for human aldolase B.
Haimoto H; Kurobe N; Hosoda S; Kato K
Laboratory of Pathology, Aichi Cancer Center Research Institute, Nagoya,
Japan.
Clin Chim Acta Apr 28 1989, 181 (1) p27-36, ISSN 0009-8981
Journal Code: DCC
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/17 (Item 17 from file: 155)
06891493 89193493
C3 binds covalently to the C gamma 3 domain of IgG immune aggregates
during complement activation by the alternative pathway.
Anton LC; Alcolea JM; Sanchez-Corral P; Marques G; Sanchez A; Vivanco F
Department of Immunology, Fundacion Jimenez Diaz, Madrid, Spain.
Biochem J Feb 1 1989, 257 (3) p831-8, ISSN 0264-6021 Journal Code:
9YO
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/18 (Item 18 from file: 155)
06766852 89068852
Inhibition of rhinovirus attachment by neutralizing monoclonal antibodies
and their Fab fragments.
Colonno RJ; Callahan PL; Long WJ; Duechant DO; Tomassini JE

Merck Sharp and Dohme Research Laboratories, West Point, Pennsylvania
19486.
J Virol Jan 1989, 63 (1) p36-42, ISSN 0022-538X Journal Code: KCV
Contract/Grant No.: AI24939
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/19 (Item 19 from file: 155)
06730765 89032765
Large scale production and purification of paraquat and desipramine
monoclonal antibodies and their Fab fragments.
Bowles M; Johnston SC; Schoof DD; Pentel PR; Pond SM
Department of Medicine, University of Queensland, Princess Alexandra
Hospital, Brisbane, Australia.
Int J Immunopharmacol 1988, 10 (5) p537-45, ISSN 0192-0561 Journal Code: GRI
Contract/Grant No.: ES03803
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/20 (Item 20 from file: 155)
06587700 88232700
Streptococcal protein G has affinity for both Fab- and Fc-fragments of
human IgG.
Erntell M; Myhre EB; Sjobring U; Bjorck L
University of Lund, Department of Infectious Diseases, University

Hospital, Sweden.
Mol Immunol Feb 1988, 25 (2) p121-6, ISSN 0161-5890 Journal Code:
NGI
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/21 (Item 21 from file: 155)
06529459 88174459
Resistance of normal serum IgA and secretory IgA to bacterial IgA
proteases: evidence for the presence of enzyme-neutralizing antibodies in
both serum and secretory IgA, and also in serum IgG.
Kobayashi K; Fujiyama Y; Hagiwara K; Kondoh H
Department of Pediatrics, Yamaguchi University School of Medicine.
Microbiol Immunol 1987, 31 (11) p1097-106, ISSN 0385-5600 Journal Code: MX7
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/22 (Item 22 from file: 155)
03495291 89140291
Protein L. A novel bacterial cell wall protein with affinity for Ig L
chains.
Bjorck L
Department of Medical Microbiology, University of Lund, Sweden.

J Immunol Feb 15 1988, 140 (4) p1194-7, ISSN 0022-1767
Journal Code: IFB
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/23 (Item 23 from file: 155)
03477154 88122154
The heterogeneity of bovine IgG2--III. The ion-exchange heterogeneity of
IgG2a is the result of VH-region variation.
Butler JE; Borca MV; Heyermann H; Dillender M; Bielecka M
University of Iowa Medical School, Department of Microbiology, Iowa City
52242.
Mol Immunol Dec 1987, 24 (12) p1317-26, ISSN 0161-5890
Journal Code: MGI
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/24 (Item 24 from file: 155)
03420469 88255469
[Intramolecular mobility of human major histocompatibility complex
protein. A spin-label study]

Vnutrimolekuliarnaia podvizhnost' belkov glavnogo kompleksa
gistosovmestimosti cheloveka. Issledovanie metodom spinovoi metki.
Mezlin RS; Pankratova EV; Kul'gushkin VV; Amuriunian AE; Tikofeev VP
Mol Biol (Mosk) Sep-Oct 1987, 21 (5) p1426-34, ISSN 0026-8984
Journal Code: MGX
Languages: RUSSIAN Summary Languages: ENGLISH
Document type: JOURNAL ARTICLE English Abstract

10/3/25 (Item 25 from file: 155)
03317061 87291861
Enzymatic fragmentation of an unusual human IgG2 (Mve) myeloma protein.
Vogt RA; Michaelsen TE
Scand J Immunol Jul 1987, 26 (1) p59-69, ISSN 0300-9475
Journal Code: USM
Languages: ENGLISH
Document type: JOURNAL ARTICLE

06814058 87130058
Binding to cellular of IgG from patients with interstitial lung
disease.
Dewair M; Baum M
Clin Chim Acta Feb 27 1987, 163 (1) p87-95, ISSN 0009-8981
Journal Code: BCC
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/27 (Item 27 from file: 155)
06136774 87110774
Identification of immunoreactive monoclonal antibody fragments for
improved immunoscintigraphy.
Mather SJ; Dunbin M; Taylor-Papadimitriou J
J Immunol Methods Feb 11 1987, 96 (2) p255-64, ISSN 0022-1759
Journal Code: IFE
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/28 (Item 28 from file: 155)
06859625 87030625
The molecular organization of the protein MC-IgG complex (MC-IgA).
Grubb A; Mendez E; Fernandez-Luna JL; Lopez C; Mihaesco E; Vaerman JP
J Biol Chem Oct 25 1986, 261 (30) p14213-20, ISSN 0021-9258

Journal Code: HIV
Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/29 (Item 29 from file: 155)
06856242 87030342
Comparative imaging and biodistribution studies with an anti-CEA
monoclonal antibody and its F(ab')2 and Fab fragments in mice with colon
carcinoma xenografts.
Andrew SM; Pimm MV; Perkins AC; Baldwin RW
Eur J Nucl Med 1986, 12 (4) p168-75, ISSN 0340-6997
Journal Code:
ENC
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/30 (Item 30 from file: 155)
06855509 86855509
Preparation of F(ab')2 fragments from mouse IgG of various subclasses.
Lamoyi E
Methods Enzymol 1986, 121 p652-63, ISSN 0076-6879 Journal

Code: MVA
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/31 (Item 31 from file: 155)
05856756 86157756
Dermatitis herpetiformis: 'pH optimum' for the release of potentially
antigen-binding IgA fragments from papillary dermis of uninvolved skin by
peptic digestion.
Egelrud T; Back O
Arch Dermatol Res 1985, 278 (1) p44-8, ISSN 0340-3696
Journal Code: 6X7
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/32 (Item 32 from file: 155)
05680021 85296021
Preparation and biologic characterization of fragments containing dimeric
and monomeric C gamma 2 domain of rabbit IgG.
Utsumi S; Okada M; Udaka K; Amano T
Mol Immunol Jul 1985, 22 (7) p811-9, ISSN 0161-5890
Journal Code:
MGI
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/33 (Item 33 from file: 155)
05543152 85159152
Dermatitis herpetiformis: biochemical properties of the granular deposits
of IgA in papillary dermis. Characterization of SDS-soluble IgA-like
material and potentially antigen-binding IgA fragments released by pepsin.
Egelrud T; Back O
J Invest Dermatol Apr 1985, 84 (4) p239-45, ISSN 0022-202X
Journal Code: IHZ
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/34 (Item 34 from file: 155)
05515506 85131506
One-step procedure for the rapid isolation of mouse monoclonal antibodies
and their antigen binding fragments by fast protein liquid chromatography
on a mono Q anion-exchange column.
Clezardin P; McGregor JL; Manach M; Boukerche H; Dechavanne M
J Chromatogr Jan 25 1985, 319 (1) p67-77, ISSN 0021-9673
Journal Code: HQF
Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/35 (Item 35 from file: 155)
05457807 85073807
Immunoglobulin Gi Fc in colostral whey.
Nielsen K; Stiller J; Sowa B
Can J Comp Med Oct 1984, 48 (4) p410-3, ISSN 0008-4050
Journal Code: CI0
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/36 (Item 36 from file: 155)
05451366 85067366
[Isolation of the Fab fragment from immune serum]
Poluchavane na Fab-fragment ot imunni serumi.
Chenchev I; Vasileva L
Vet Med Nauki 1984, 21 (7-8) p44-8, ISSN 0324-1068
Journal Code:
XCE
Languages: BULGARIAN Summary Languages: ENGLISH
Document type: JOURNAL ARTICLE English Abstract

10/3/37 (Item 37 from file: 155)
05431279 85047279
Interaction of porcine immunoglobulin M with protein A of Staphylococcus
aureus.
Gentile TC; Dierks SE; Watt RM
Biochim Biophys Acta Nov 23 1984, 791 (1) p102-11, ISSN 0006-3002
Journal Code: A0W
Contract/Grant No.: BRS-E-195J; HL29340

Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/38 (Item 38 from file: 155)
05374007 84298007
[Proteolysis of horse blood serum proteins at various stages of antitoxic
sera production by the Diaferm-3 method]
O proteolize belkov syvorotki krovi loshadi na razlichnykh stadiiakh
polucheniia antitoksicheskikh syvorotok po metodu "Diaferm-3".
Grechushkina-Sukhorukova NA; Tel'bukh VP; Stepanov VM
Prikl Biokhim Mikrobiol Jul-Aug 1984, 20 (4) p528-33, ISSN 0555-1099
Journal Code: PM5
Languages: RUSSIAN Summary Languages: ENGLISH
Document type: JOURNAL ARTICLE English Abstract

10/3/39 (Item 39 from file: 155)
05317147 84241147
Purification and some properties of streptococcal protein

IgG-binding reagent.
Bjorck L; Kronvall G
J Immunol Aug 1984, 133 (2) p969-74, ISSN 0022-1767
Journal Code:
IFB
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/40 (Item 40 from file: 155)
05139023 84063023
Optimal conditions for the preparation of Fab and F(ab')2 fragments from
monoclonal IgG of different rat IgG subclasses.
Rousseaux J; Rousseaux-Prevost R; Bazin H
J Immunol Methods Nov 11 1983, 64 (1-2) p141-6, ISSN 0022-1759
Journal Code: IFE
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/41 (Item 41 from file: 155)
05129397 84053397
Disulfide linking of albumin to the hinge region of immunoglobulin G in
normal human serum.
Mohammad SF; Sharma N; Woodward SC
Biochim Biophys Acta Nov 28 1983, 749 (1) p47-51, ISSN 0006-3002
Journal Code: A0W
Contract/Grant No.: HL-25804; HL-25806
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/42 (Item 42 from file: 155)
04954594 83187594
Simplified preparation of rabbit Fab fragments.
Coulter A; Harris R
J Immunol Methods Apr 29 1983, 59 (2) p199-203, ISSN 0022-1759
Journal Code: IFE
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/43 (Item 43 from file: 155)
04829514 83062514
An unusual papain cleavage of a human IgG1 (lambda) myeloma protein
(Mot).
Kojima M; Odani S; Ono T
Mol Immunol Sep 1982, 19 (9) p1095-103, ISSN 0161-5890
Journal Code: M6I
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/44 (Item 44 from file: 155)
04704942 82247942
Antibodies to RNA from autoimmune NZB/NZW mice recognize a similar
antigenic determinant and show a large idiotypic diversity.
Eilat D; Hochberg M; Fischel R; Laskov R
Proc Natl Acad Sci U S A Jun 1982, 79 (12) p3818-22, ISSN 0027-8424
Journal Code: PV3
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/45 (Item 45 from file: 155)
04569229 82112229
Enzymatic and immunochemical properties of lysozyme--restriction of
recognition of lysozyme antigenic determinants in pigs.
Habeeb AF
Arch Biochem Biophys Dec 1981, 212 (2) p618-28, ISSN 0003-9861
Journal Code: 6SK
Contract/Grant No.: AI-14791
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/46 (Item 46 from file: 155)
04503815 82046815
A comparison of the actions of trypsin and pepsin on porcine
immunoglobulin M and their effects on biological activity.
Beale D; Fazakerley JK
Biochim Biophys Acta Sep 29 1981, 670 (2) p230-5, ISSN

0006-3002
Journal Code: A6W
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/47 (Item 47 from file: 155)
04382697 81210697
Site of alkaline phosphatase attachment in alkaline
phosphatase-immunoglobulin G complexes.
Crofton PM
Clin Chim Acta Apr 27 1981, 112 (1) p33-42, ISSN 0009-8981
Journal Code: DCC
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/48 (Item 48 from file: 155)
04305566 81133566
The action of pepsin on porcine immunoglobulin M and its effect on
biological activity.

Beale D; Beckerley JM
Biochem J Oct 1 1980, 191 (1) p183-91, ISSN 0006-2936 Journal Code: 9YO
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/49 (Item 49 from file: 155)
04240436 81068436
Immunoglobulin produced by guinea-pig leukaemic B lymphocytes: its source
and use as a monitor of tumour load.
Stevenson FK; Morris D; Stevenson GT
Immunology Oct 1980, 41 (2) p313-21, ISSN 0019-2805 Journal Code:
GH7
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/50 (Item 50 from file: 155)
04187392 81015392
Kinetics of the different susceptibilities of the four human
immunoglobulin G subclasses to proteolysis by human lysosomal elastase.
Baici A; Knopfel M; Fehr K; Skvaril F; Boni A
Scand J Immunol 1980, 12 (1) p41-50, ISSN 0300-9675 Journal Code:
UCW
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/51 (Item 51 from file: 155)
03909920 80020920

The crystallizable human myeloma protein Dob has a hinge-region deletion.
Steiner LA; Lopes AD
Biochemistry Sep 18 1979, 18 (19) p4054-67, ISSN 0006-2960 Journal Code: A0G
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/52 (Item 52 from file: 155)
03905762 80016762
Isolation of enzymatically derived fragments of porcine IgG and an
examination of their reactivity against staphylococcal protein A.

Endresen C
Acta Pathol Microbiol Scand [C] Jun 1979, 87C (3) p177-83, ISSN
0304-1328 Journal Code: 103
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/53 (Item 53 from file: 155)

03807467 79184467
Purification and characterization of rabbit anti-mouse renin specific Fab
fragments.
Lykkegard S
Acta Pathol Microbiol Scand [C] Apr 1979, 87C (2) p91-7, ISSN
0304-1328 Journal Code: 103
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/54 (Item 54 from file: 155)
03665153 79042153
An IgG2a-producing variant of an IgG2b-producing mouse myeloma cell line.
Structural studies on the Fc region of parent and variant heavy chains.
Francus T; Birshtein BK
Biochemistry Oct 3 1978, 17 (20) p4324-31, ISSN 0006-2960
Journal Code: A0G
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/55 (Item 55 from file: 155)
03641119 79018119
Isolation of enzymatically derived fragments of guinea pig IgG and an
examination of their reactivity against Staphylococcal protein A.

Endresen C; Grov A
Acta Pathol Microbiol Scand [C] Aug 1978, 86C (4) p193-8, ISSN

0304-1328 Journal Code: 103
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/56 (Item 56 from file: 155)
03579573 78213573
The immunoglobulin nature of nephritic factor (NeF).
Scott DM; Amos N; Sissons JG; Lachmann PJ; Peters DK
Clin Exp Immunol Apr 1978, 32 (1) p12-24, ISSN 0009-9104
Journal Code: DD7
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/57 (Item 57 from file: 155)
03237866 77139866
Enzymatic fragmentation of human IgA F(abc)'2: a new peptic fragment.
Rivat C; Bourguignon J; Fontaine M; Ropartz C
Immunochemistry Jan 1977, 14 (1) p69-73, ISSN 0019-2791
Journal Code: GH2
Languages: ENGLISH

10/3/58 (Item 58 from file: 155)
03050489 76231489
Fb'2, a new peptic fragment of human immunoglobulin G.
Parr DM; Connell GE; Kells DI; Hofmann T
Biochem J Apr 1 1976, 155 (1) p31-6, ISSN 0006-2936
Journal Code:
9Y0
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/59 (Item 59 from file: 155)
03011396 76192396
Biologic activities of rabbit immunoglobulin G in relation to domains of
the Fc region.
Ovary Z; Saluk PH; Quijada L; Lamm ME
J Immunol May 1976, 116 (5) p1265-71, ISSN 0022-1767
Journal Code:
IFB
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/60 (Item 60 from file: 155)
02741551 75148551
[Study of the products of pepsin digestion of dimeric forms of human
serum IgA]
Etude des produits de digestion par la pepsine des formes dimeriques des
IgA seriques humaines
Rivat C; Bourguignon J; Fontaine M; Ropartz C

C R Acad Sci Hebd Seances Acad Sci D Oct 14 1974, 279 (16) p1405-7,
ISSN 0567-655X Journal Code: C9C
Languages: FRENCH
Document type: JOURNAL ARTICLE

10/3/61 (Item 61 from file: 155)
02727375 75134375
The isolation and characterization of the V-H domain from rabbit heavy
chains of different a locus allotype.
Mole LE; Geier MD; Koshland ME
J Immunol May 1975, 114 (5) p1442-8, ISSN 0022-1767
Journal Code:
IFB
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/62 (Item 62 from file: 155)
02621414 75028414
Fragmentation and reduction of porcine 19 S immunoglobulin M.

FEBS Lett Aug 25 1974, 44 (2) p236-40, ISSN 0014-5793
Journal Code: EBL
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/62 (Item 63 from file: 155)
02452447 74171447
Peptic digestion of pig IgM.
Zikan J; Miler I
Immunochemistry Mar 1974, 11 (3) p215-8, ISSN 0019-2791
Journal Code: CM2
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/64 (Item 64 from file: 155)
02424449 74132449
MU-chain disease in an African patient.
Bonhomme J; Seligmann M; Mihaesco C; Clauvel JP; Danon F;
Brouet JC;
Bouvry P; Martine J; Clerc M
Blood Apr 1974, 43 (4) p495-02, ISSN 0006-4971 Journal
Code: R8C
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/65 (Item 65 from file: 155)
02357359 74075359
Characterization of subclass-related F(ab)2, Fab-c and Fab
fragments
obtainined by short papain digestion of human IgG myeloma
proteins.
Michaelsen TE; Natvig JB

Scand J Immunol 1973, 2 (3) p209-212, ISSN 0300-9807
Journal Code:
ISM
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/66 (Item 66 from file: 155)
02252295 74010295
Specific heterologous enhancement of immune responses. V.
Isolation of a
soluble enhancing factor from supernatants of specifically
stimulated and
allogeneically induced lymphoid cells.
Rubin BS; MacDonald RR; Coons RM
J Immunol Nov 1973, 111 (5) p1314-25, ISSN 0022-1767
Journal Code:
IFB
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/67 (Item 67 from file: 155)

Three new fragments, F(ab') 2 , F(a) 2 , and Fab-c, obtained by papain
proteolysis of normal human IgG.
Michaelsen TE; Natvig JB
Scand J Immunol 1972, 1 (3) p255-68, ISSN 0300-9807
Journal Code:
USM
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/68 (Item 68 from file: 155)
02054924 72023924
Atypical immunoglobulins associated with spontaneous lymphomas in an
inbred strain of mice.
Schrohenloher RE; Bailey PC
J Natl Cancer Inst Oct 1972, 49 (4) p1027-37, ISSN 0027-0874
Journal Code: J9J
Languages: ENGLISH
Document type: JOURNAL ARTICLE

10/3/69 (Item 1 from file: 55)
0083678 BIOSIS Number: 91004678
CRYSTALLIZATION AND PRELIMINARY X-RAY DIFFRACTION STUDIES OF THE FAB
FRAGMENT OF A NEUTRALIZING MONOCLONAL ANTIBODY DIRECTED AGAINST HUMAN
RHINOVIRUS SEROTYPE 2
TORNO J; FITA I; KANZLER G; BLAAS D
DEP. D'ENGINYERIA QUIMICA, ESCOLA TECNICA SUPERIOR D'ENGINYERS INDUSTRIALS DE BARCELONA, UNIVERSITAT POLITECNICA DE CATALUNYA,

DIAGONAL
647, E-28021 BARCELONA, SPAIN.
J BIOL CHEM 265 (28). 1990. 16799-16800. CODEN: JBCHA
Full Journal Title: Journal of Biological Chemistry
Language: ENGLISH

10/3/70 (Item 2 from file: 55)
7162782 BIOSIS Number: 00035465
UNIQUE FEATURES OF MONOCLONAL IGG2B IN THE CLEAVAGE REACTION WITH PEPSIN
SUMII H; TSUTSUI K; MATSUSHIMA M; INOUE H; TANABE S; ODA T
DEP. ORTHOPEDIC SURG., OKAYAMA UNIV. MED. SCH., CANCER INST., OKAYAMA
UNIV. MED. SCH., OKAYAMA 700, JPAN.
ACTA MED OKAYAMA 43 (2). 1989. 125-142. CODEN: AMOKA
Full Journal Title: Acta Medica Okayama
Language: ENGLISH

10/3/71 (Item 3 from file: 55)
6504095 BIOSIC Number: 05104616
PROTEIN L A NOVEL BACTERIAL CELL WALL PROTEIN WITH AFFINITY FOR

CHAINS
BJORCK L
DEP. MED. MICROBIOL., UNIV. LUND. SOLVEGATAN 23, S-223 62 LUND, SWEDEN.
J IMMUNOL 140 (4). 1988. 1194-1197. CODEN: JOIMA
Full Journal Title: Journal of Immunology
Language: ENGLISH

10/3/72 (Item 4 from file: 55)
5761983 BIOSIS Number: 83024298
THE MOLECULAR ORGANIZATION OF THE PROTEIN HC-IMMUNOGLOBULIN A COMPLEX
SRUBB A; MENDEZ E; FERNANDEZ-LUNA J L; LOPEZ C; MIHAESCO E; VAERMAN J-P
DEP. CLINICAL CHEM., UNIV. LUND, MALMO GENERAL HOSP., S-214 01 MALMO, SWED.
J BIOL CHEM 261 (30). 1986. 14313-14320. CODEN: JBCHA
Full Journal Title: Journal of Biological Chemistry
Language: ENGLISH

10/3/73 (Item 5 from file: 55)
5299014 BIOSIS Number: 81053321
DERMATITIS HERPETIFORMIS PH OPTIMUM FOR THE RELEASE OF POTENTIALLY
ANTIGEN-BINDING IMMUNOGLOBULIN A FRAGMENTS FROM PAPILLARY DERMIS OF
UNINVOLVED SKIN BY PEPTIDE DIGESTION
EGELRUD T; BAECK O
DEP. DERMATOL., UNIV. HOSP. ,S-901 85 UMEA, SWEDEN.
ARCH DERMATOL REG 278 (1). 1985. 44-48. CODEN: ADRED
Full Journal Title: Archives of Dermatological Research

Language: ENGLISH

10/3/74 (Item 6 from file: 55)
4886048 BIOSIS Number: 80013359
DERMATITIS HERPETIFORMIS BIOCHEMICAL PROPERTIES OF THE GRANULAR DEPOSITS
OF IMMUNOGLOBULIN A IN PAPILLARY DERMIS CHARACTERIZATION OF SODIUM DODECYL
SULFATE-SOLUBLE IMMUNOGLOBULIN A-LIKE MATERIAL AND POTENTIALLY
ANTIGEN-BINDING IMMUNOGLOBULIN A FRAGMENTS RELEASED BY PEPSIN
EGELRUD T; BACK O
DEPARTMENT OF DERMATOLOGY, UNIVERSITY HOSPITAL, S-921 85 UMEA, SWEDEN.
J INVEST DERMATOL 84 (4). 1985. 239-245. CODEN: JIDEA
Full Journal Title: Journal of Investigative Dermatology
Language: ENGLISH

10/3/75 (Item 7 from file: 55)
4779886 BIOSIS Number: 79022201
PURIFICATION AND SOME PROPERTIES OF STREPTOCOCCAL PROTEIN G A NOVEL

IMMUNOGLOBULIN G-BINDING MEMBER?
BJORCK L; KRONVALL G
DEP. MED. MICROBIOL., SOLVEGATAN 23, S-223 62 LUND, SWED.
J IMMUNOL 133 (2). 1984. 969-974. CODEN: JOIMA
Full Journal Title: Journal of Immunology
Language: ENGLISH
?

AT E1 V1 X0 DT3059488
CONNECT

Enter terminal type or "M" for menu - KSR

PLEASE ENTER HOST PORT ID:x
LOGINID:di86rbs
PASSWORD:##########^H^H^H^H^H^H^H^H^H^HIIIIIIIII^H^H^H^H^H^H^H^H^H^H##
^ H ^ H ^ H ^ H ^ H ^ H ^ H ^ H d u d e
PASSWORD:##########^H^H^H^H^H^H^H^H^H^HIIIIIIIII^H^H^H^H^H^H^H^H^H^H##
########^H^H^H^H^H^H^H^H^H^H
TERMINAL (ENTER 1, 2, 3, 4, OR ?):3

* *

*   *

*   Welcome to MESSENGER at USPTO   *

*   *

* *

* The USPTO production files are current through: *

* 02 FEB 1993 for U.S. Patent Text Data *

* 02 FEB 1993 for U.S. Current Classification data. *

* 02 FEB 1993 for U.S. Patent Image Data. *

* *

* *

* * PLEASE USE 305-9000 FOR NEW TELEPHONE NUMBER * *

* *

* *

* DISCLAIMER: *

* Neither the United States Government, nor any agency *

* thereof, nor any of their contractors, subcontractors or *

* employees make any warranty, expressed or implied, *

* including any warranty of marketability of fitness for a *

* particular purpose; nor assumes any legal liability or *

* responsibility for any party's use, or the results of *

* such, of the data. *

* *

* *

* There is a new number to call for APS help: 305-9000. *

* The Help Desk staff at this number will handle all APS *

* related questions. Current hours are 6:30 am to 9:00 pm *

* Monday through Friday and 7:30 am to 5:00 pm Saturday. *

* *

* HOURS TO ACCESS MESSENGER ARE 6:30 AM to 9:00 PM *

* MONDAY THRU FRIDAY AND 7:30 AM to 5:00 PM SATURDAY. *

```
  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

FILE 'USPAT' ENTERED AT 11:34:27 ON 04 FEB 93

  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

  *            W E L C O M E   T O   T H E                    *

  *        U. S.   P A T E N T   T E X T   F I L E            *

  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *


=) s venom or antivenin
          682 VENOM
            4 ANTIVENIN
L1        682 VENOM OR ANTIVENIN

=) s fab or fab2 or f(ab) or f(ab)2
MISSING OPERATOR 'OR F(AB'

=) s fab or fab2 or f(ab) or f(ab)2
MISSING OPERATOR 'OR F(AB'
YOU HAVE RECEIVED THIS ERROR MESSAGE  2 CONSECUTIVE TIMES
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.
IF YOU REQUIRE FURTHER HELP, PLEASE CONTACT YOUR LOCAL HELP DESK
=) s fab or fab2 or f(ab) or f(ab)2
MISSING OPERATOR 'OR F(AB'

=) s fab or fab2
         2470 FAB









            0 FAB2
L2       2470 FAB OR FAB2

=) s l2 and l1
L3         39 L2 AND L1

=) t l3 cit ab 1-39

1.  5,180,820, Jan. 19, 1993, Brain-derived neurotrophic factor;
Yves-Alain  Barde,  et  al., 536/23.51;  435/69.1,  69.3,  172.3,
320.1;
530/399, 412 [IMAGE AVAILABLE]

US PAT NO:      5,180,820 [IMAGE AVAILABLE]              L3: 1 of
39

ABSTRACT:
The present invention relates  to nucleic acid sequences encoding
brain
derived  neurotrophic  factor (BDNF),  as  well  as BDNF  protein
produced in
```

and
derivatives thereof. In addition, the invention relates to pharmacologic
compositions and therapeutic uses of BDNF, having provided, for the first
time, the ability to generate sufficient quantities of substantially pure
BDNF for clinical use. The invention also relates to antibodies directed
toward BDNF or fragments thereof, having provided a method for generating
sufficient immunogen. Further, by permitting a comparison of the nucleic
acid sequences of BDNF and NGF, the present invention provides for the
identification of homologous regions of nucleic acid sequence between
BDNF and NGF, thereby defining a BDNF/NGF gene family; the invention
provides a method for identifying an dicsolating additional members of
this gene family.

2. 5,175,273, Dec. 29, 1992, Nucleic acid intercalating agents; Norbert
W. Bischofberger, et al., 536/27, 1.1, 18.7, 22, 23, 28, 29 [IMAGE
AVAILABLE]

US PAT NO: 5,175,273 [IMAGE AVAILABLE] L3: 2 of 39

ABSTRACT:
Pyridinone or pyrimidinone nucleoside bases containing fused aromatic
polycyclic rings are provided. These polycyclic nucleosides are
incorporated into oligonucleotides and hybridized to complementary
nucleic acid. Fluorescence spectroscopy and thermal denaturation profiles
provided evidence that the polycyclic base is intercalated into the
resulting duplex. The fused polycyclic ring systems optionally are
substituted with reactive species which inactivate complementary nucleic
acids. The oligonucleotides of this invention are useful as improved
probes, diagnostic reagents, or for cleaving or derivatizing
predetermined domains within nucleic acids.

2. 5,171,864, Dec. 15, 1992, Di-(5-hydroxy-2(E)-2-cne-4-fury)]methyl-

furyl)methyl-alpha,omega-dialkanoic acid amides as anti-inflammatory
agents; Gary C. M. Lee, 549/222, 318 [IMAGE AVAILABLE]

US PAT NO: 5,171,864 [IMAGE AVAILABLE] L3: 3 of 39

ABSTRACT:
Compounds of the formula ##STR1## in which R.sub.1 independently is H or
alkyl of 1 to 20 carbons, CO--R.sub.2, CO--O--R.sub.2, CO--NH--R.sub.2,
or PO(OR.sub.2).sub.2 or PO(OR.sub.2)R.sub.2, where R.sub.2 independently
is H, alkyl of 1 to 20 carbons, phenyl, or lower alkyl substituted phenyl
or halogen substituted phenyl; A is (CH.sub.2).sub.n where n ranges
between 5 to 30, or A is a a divalent branch chained alkyl radical, or
cycloalkyl radical, having a total of 5 to 30 carbons, and X is O or NH,
have anti-inflammatory activity.

4. 5,169,963, Dec. 8, 1992, Di-(5-hydroxy-2(5H)2-oxo-4-furyl)alkylmethyl-
alpha,omega alkanedioates and N,N-bis-(5-hydroxy-2(5H)2-oxo-4-
furyl)alkylmethyl-alpha,omega-dialkanoic acid amides as anti-inflammatory
agents; Gary C. M. Lee, 549/222, 318 [IMAGE AVAILABLE]

US PAT NO: 5,169,963 [IMAGE AVAILABLE] L3: 4 of 39

ABSTRACT:
Compounds of the formula ##STR1## in which R.sub.1 independently is H or
alkyl of 1 to 29 carbons, CO-R.sub.2, CO-O-R.sub.2, CO-NH-R.sub.2, or
PO(OR.sub.2).sub.2 or PO(OR.sub.2)R.sub.2, where R.sub.2 independently is
H, alkyl of 1 to 20 carbons, phenyl, or lower alkyl substituted phenyl or
halogen substituted phenyl; A is (CH.sub.2).sub.n where n ranges between
0 to 30, or A is a a divalent branch chained alkyl radical, or cycloalkyl
radical, having a total of 3 to 30 carbons; R.sub.3 independently is an
alkyl group having 4 to 20 carbons, and X is O or NH, have
anti-inflammatory activity.

5. 5,169,933, Dec. 8, 1992, Covalently-linked complexes and methods for

enhanced cytotoxicity and imaging; David C. Anderson, et al., 530/391.3;
424/1.1, 9, 85.91; 530/386, 387, 388, 313, 323, 324, 325, 326, 327, 328,
329, 330, 351, 377, 391.1, 391.5, 391.7, 391.9, 395, 399, 403, 408, 409,
410 [IMAGE AVAILABLE]

US PAT NO: 5,169,933 [IMAGE AVAILABLE] L3: 5 of 39

ABSTRACT:
Covalently-linked complexes (CLCs) for targeting a defined population of
cells, comprising a targeting protein; a cytotoxic agent; and an enhancing moiety, wherein the enhancing moiety is capable of promoting
CLC-target cell interaction are disclosed. Methods for using the claimed
CLCs to obtain enhanced in vivo cytotoxicity and enhanced in vivo imaging
are also described.

6. 5,162,504, Nov. 10, 1992, Monoclonal antibodies to a new antigenic
marker in epithelial prostatic cells and serum of prostatic cancer
patients; Julius S. Horoszewicz, 530/388.2; 435/7.23, 70.21, 240.27;
530/388.8 [IMAGE AVAILABLE]

US PAT NO: 5,162,504 [IMAGE AVAILABLE] L3: 6 of 39

ABSTRACT:
Monoclonal antibodies to prostatic cells, are produced by a hybridoma
formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies show specificity for a non-soluble, membrane
associated, organ specific antigenic determinant limited in its distribution to normal and neoplastic, human prostate epithelial cells.
The monoclonal antibodies, specifically 7E11-C5 monoclonal antibodies,
may be suitable for diagnostic uses.

7. 5,159,085, Oct. 27, 1992, 2-anilino phenylacetic acid derivatives as
inhibitors of PLA.sub.2 and lipoxygenase; Amedeo A. Failli, et al.,
548/310.1, 341.1, 342.5 [IMAGE AVAILABLE]

US PAT NO: 5,159,085 [IMAGE AVAILABLE] L3: 7 of

US PAT NO: 5,167,888 [IMAGE AVAILABLE] L3: 7 of 39

ABSTRACT:
There are disclosed compounds of the formula ##STR1## wherein R is
hydroxy, lower alkoxy or lower alkoxyamino;
R.sup.1 is hydrogen or A(CH.sub.2).sub.n O--;
R.sup.2 is hydrogen or A(CH.sub.2).sub.n O--, with the proviso that one
of R.sup.1 and R.sup.2 is hydrogen;
n is 1-2;
A is phenoxyethyl, phenoxyphenyl or a group having the formula ##STR2##
R.sup.3 is hydrogen, lower alkyl or phenyl; R.sup.4 is hydrogen or
lower alkyl; or
R.sup.3 and R.sup.4 taken together form a benzene ring;
R.sup.5 is hydrogen or lower alkyl;
R.sup.6 is hydrogen, halo or lower alkyl;
and the pharmacologically acceptable salts thereof, and their use in the
treatment of inflammatory conditions, such as rheumatoid arthritis,
ulcerative colitis, psoriasis and other immediate hypersensitivity
reactions; in the treatment of leukotriene-mediated naso-bronchial
obstructive air-passageway conditions, such as allergic rhinitis,
allergic bronchial asthma and the like; and as gastic cytoprotective
agents.

8. 5,156,840, Oct. 20, 1992, Amine-containing porphyrin derivatives;
John W. F. Goers, et al., 424/85.91; 514/410 [IMAGE AVAILABLE]

US PAT NO: 5,156,840 [IMAGE AVAILABLE] L3: 8 of 39

ABSTRACT:
The invention relates to amine-containing porphyrin derivatives.
Theporphyrins can be used as photosensitizers which are useful as
therapeutic agents. Also described are methods for preparing conjugates
in which a porphyrin derivative is covalently attached to an antibody or
antibody fragment. In vivo therapeutic methods utilizing the conjugates
are also desired.

9. 5,135,736, Aug. 4, 1992, Covalently-linked complexes and

enhanced cytotoxicity and imaging; David C. Anderson, et al., 424/1.1, 9,
85.91, 94.3; 435/188; 514/8, 12, 21; 530/387.1, 388.15, 388.8, 389.7,
391.3, 391.7, 395 [IMAGE AVAILABLE]

US PAT NO: 5,135,736 [IMAGE AVAILABLE] L3: 9 of 39

ABSTRACT:
Covalently-linked complexes (CLCs) for targeting a defined population of
cells, comprising a targeting protein or peptide; a cytotoxic agent; and
an enhancing moiety, wherein the enhancing moiety is capable of promoting
CLC-membrane interaction are disclosed. Methods for using the claimed
CLCs to obtain enhanced in vivo cytotoxicity and enhanced in vivo imaging
are also described.

10. 5,120,537, Jun. 9, 1992, Factor Xa based anticoagulant compositions;
Charles T. Esmon, et al., 424/94.64; 435/69.6, 212, 226; 514/2, 12, 21;
530/381 [IMAGE AVAILABLE]

US PAT NO: 5,120,537 [IMAGE AVAILABLE] L3: 10 of 39

ABSTRACT:

An anticoagulant composition containing an effective amount of factor Xa
having the active serine site inactivated that functions rapidly and
effectively in vivo to suppress coagulation. In a preferred embodiment,
Factor Xa, a serine esterase that forms a complex with Factor Va, Ca++,
and phospholipid to catalyze prothrombin activation, is first inactivated
with an active site inhibitor, such as dansyl-glu-gly-arg-chloromethyl
ketone, to form inactivated factor Xa. In another embodiment, Factor Xa
is expressed from a gene sequence wherein the portion encoding the active
serine region is modified. The inactivated protein retains the ability to
bind to endogenous factor Va in vivo, and has a half-life of
approximately ten hours. Administration of inactive factor Xa to the

blood of a patient results in the formation of inactive Fac.
Xa-Va
complexes in vivo, thereby inhibiting coagulation.

11. 5,112,739, May 12, 1992, Enzyme controlled release system; Frank A.
Meneghini, et al., 435/14, 4, 18, 19, 21, 24, 183; 436/546 [IMAGE

AVAILABLE]

US PAT NO: 5,112,739 [IMAGE AVAILABLE] L3: 11 of 39

ABSTRACT:
This invention relates to an enzyme-controlled release method for the
release of a leaving group comprising:
contacting a compound represented by the formula ##STR1## wherein R,
R.sub.1, R.sub.2 and R.sub.3 each independently is hydrogen, a
substituent affecting the mobility or reactivity of the compound or a
substituent including a biologically active group;
X is leaving group;
Z is an enzyme substrate moiety;
--CR.sub.2 R.sub.3 X is either ortho or para to the --O--Z moiety;
with an active capable of cleaving said enzyme substrate moiety Z from
said compound;
whereby said leaving group X is released from said compound.

12. 5,086,002, Feb. 4, 1992, Erythrocyte agglutination assay;

Carmel J.
Hillyard, et al., 436/540; 422/61; 435/7.25; 436/501, 519; 530/387.3,
388.7, 389.1, 866 [IMAGE AVAILABLE]

US PAT NO: 5,086,002 [IMAGE AVAILABLE] L3: 12 of 39

ABSTRACT:
In a novel, erythrocyte agglutination assay, the agglutination reagent
comprises at least one erythrocyte binding molecule coupled to at least
one specific analyte binding molecule wherein the erythrocyte binding
molecule does not cause agglutination when incubated with erythrocytes in
the absence of analyte (in the case of a direct assay) or analyte binding
reagent (in the case of an indirect assay). Preferably, the erythrocytes

blood
sample is assayed. Mixtures of conjugates and conjugates of analyte
analogues with erythrocyte binding molecules may also be used as agglutination reagents. The reagents and their use in direct or indirect
assays is disclosed.

13. . 5,081,261, Jan. 14, 1992, 4-(1-hydroxy-2-N-substituted sulfonamido)
ethyl-5-hydroxy-2(5H)-furanones and 4-(N-substituted sulfonamido)-2-
ethenyl-5-hydroxy-2(5H)-furanones as anti-inflammatory agents; Gary C. M.
Lee, 549/222; 544/229, 337, 379, 383; 549/214, 313, 318 [IMAGE AVAILABLE]

US PAT NO: 5,081,261 [IMAGE AVAILABLE] L3: 13 of 39

ABSTRACT:
Compounds of Formula 1, and of Formula 2, ##STR1## in which R.sub.1 is H
or alkyl of 1 to 20 carbons, CO--R.sub.1.sup.* CO--O--R.sub.1.sup.*
CO--NH--R.sub.1.sup.* or PO(OR.sub.1.sup.*).sub.2 or
PO(OR.sub.1.sup.*)R.sub.1.sup.* where R.sub.1.sup.* independently is H,
alkyl of 1 to 20 carbons, phenyl, or substituted phenyl; R.sub.2 is H,
alkyl of 1 to 20 carbons, or R.sub.2 and Y jointly represent a heterocycle which incorporates the sulfonamide nitrogen in the

ring as a
heteroatom; R.sub.3 is H or alkyl of 1 to 20 carbons; X is H, R.sub.4,
CO--R.sub.4, CO--O--R.sub.4, CO--NH--R.sub.4, CO--N--(R.sub.4).sub.2,
PO(OR.sub.4).sub.2 or PO(OR.sub.4)R.sub.4, and R.sub.4 independently is
H, phenyl, substituted phenyl, alkyl of 1 to 20 carbons or is alkyl of 1
to 20 carbons substituted with a hydroxyl, alkoxy, substituted amino,
thioalkoxy, with a O--COR.sub.4.sup.* group or with a COR.sub.4.sup.*
group where R.sub.4.sup.* is H, lower alkyl, OH, OR.sub.4.sup. ^_ ,
NH.sub.2, NHR.sub.4.sup. ^_ or N(R.sub.4.sup. ^_).sub.2 group where
R.sub.4.sup. ^_ independently is H or lower alkyl, with the proviso that
when X is CO--O--R.sub.4 or is CO--NH--R.sub.4 then R.sub.4 is not

hydrogen; and Y is H, phenyl or substituted phenyl; W alkyl of 2 to 20
carbons, or is alkyl of 1 to 20 carbons substituted with a hydroxyl,
alkoxy, substituted amino, thioalkoxy, O--PO(OR.sub.5).sub.2,
O--PO(OR.sub.5)R.sub.5, O--SO.sub.3 H, O--SO.sub.2 R.sub.5,
O--COR.sub.5,
or COR.sub.5 group where R.sub.5 is H, lower alkyl, OH,
OR.sub.5.sup.*,
NH.sub.2, NHR.sub.5.sup.* or N(R.sub.5.sup.*).sub.2 group where
R.sub.5.sup.* is lower alkyl, or R.sub.2 and Y jointly represent a
heterocycle which incorporates the sulfonamide nitrogen in the ring as a
heteroatom, with the proviso that when Y is an alkyl substituted with
O--PO(OR.sub.5).sub.2 or with O--PO(OR.sub.5)R.sub.5 then R.sub.5 is not
OH, are disclosed. The compounds possess anti-inflammatory activity.

14. 5,071,835, Dec. 10, 1991, Ribonucleotide reductase inhibitors; Yvan
Guindon, et al., 514/13; 15, 17, 18, 19; 530/326, 327, 328, 329 [IMAGE
AVAILABLE]

US PAT NO: 5,071,835 [IMAGE AVAILABLE] L3: 14 of 39

ABSTRACT:
Disclosed herein are peptides of the formula

Y--R.sup.1 --R.sup.2 --R.sup.3 --R.sup.4 --R.sup.5 --R.sup.6 --Z

wherein R.sup.1 to R.sup.5 are designated amino acid residues; R.sup.6 is
Phe, homoPhe or an amino acid residue derived from 2-amino-3-
cyclohexylpropionic acid, 2-amino-3-(4-(lower alkoxy)phenyl) propionic
acid or 2-amino-3-(4-halophenyl)propionic acid; Y is Phe, desamino-Phe,
(lower alkanoyl)-Phe, p-haloPhe, Tyr, desamino-Tyr or (lower
alkanoyl)-Tyr, or Y is the decapeptide radical W--Val--R.sup.7
--Ser--R.sup.8 --R.sup.9 --Thr--Glu--R.sup.10 --Ser--Phe wherein W is
hydrogen or lower alkanoyl and R.sup.7 to R.sup.10 are designated amino
acids residues, or Y is a fragment of the decapeptide radical wherein
from one to nine of the amino acid residues (i.e. Val to Ser) may be
deleted serially from the amino terminus of the decapeptide radical; and
Z is hydroxy, amino, lower alkylamino or di(lower alkyl)amino;

The
peptides inhibit mammalian ribonucleotide reductase and are indicated for
preventing or ameliorating abnormal cell proliferation.

15. 5,066,789, Nov. 19, 1991, Targeting substance-diagnostic/therapeutic
agent conjugates having Schiff base linkages; Ananthachari Srinivasan, et
al., 530/391.5, 363, 391.9 [IMAGE AVAILABLE]

US PAT NO: 5,066,789 [IMAGE AVAILABLE] L3: 15 of 39

ABSTRACT:
Targeting substance-diagnostic/therapeutic agent conjugates joined by
stabilized Schiff base or hydrazone linkages are disclosed. In addition,
slow release carrier-drug pharmaceuticals are described. The diagnostic
and therapeutic conjugates and pharmaceuticals of the present invention
provide certain advantages relating to in vivo administration, including
controlled release of the active agent at a target site.

16. 5,066,671, Nov. 19, 1991, Ellagic acid derivatives as phospholipase
A.sub.2 inhibitors; Craig E. Caufield, 514/453 [IMAGE AVAILABLE]

US PAT NO: 5,066,671 [IMAGE AVAILABLE] L3: 16 of

39

ABSTRACT:
There are disclosed a method for the treatment or prevention of
immunoinflammatory conditions by administering to a mammal an effective
amount of a compound having the formula: ##STR1## wherein R.sup.1,
R.sup.2, R.sup.3, and R.sup.4 are each, independently, hydrogen, alkyl,
aralkyl, aryl, or ##STR2## X is alkyl, aryl, or -NR.sup.5 R.sup.6 ;
R.sup.5 and R.sup.6 are each independently hydrogen, alkyl, or aryl; aryl
is ##STR3## where the dotted line represents an optional double bond;
R.sup.7, and R.sup.8 and R.sup.9 are each, independently, hydrogen,
alkyl, hydroxy, alkoxy, carbalkoxy, halo, nitro, amino, cyano,
trifluoromethyl, or a carboxylic acid;
n=1-3;

of a pharmaceutically acceptable salt thereof.

17. 5,049,390, Sep. 17, 1991, Liposome containing immunotherapy agents
for treating IgE mediated allergies; Aristo Wojdani, 424/450 [IMAGE
AVAILABLE]

US PAT NO: 5,049,390 [IMAGE AVAILABLE] L3: 17 of 39

ABSTRACT:
An immunotherapy agent for the treatment of allergy composed of an
allergen encapsulated in or covalently bound to a liposome is disclosed.
Use of the agent in immunotherapy results in enhanced IgG production and
reduced IgE production.

18. 5,037,846, Aug. 6, 1991, Indolyl-3 polyamines and their use as
antagonists of excitatory amino acid neurotransmitters; Nicholas A.
Saccomano, et al., 514/419; 548/495 [IMAGE AVAILABLE]

US PAT NO: 5,037,846 [IMAGE AVAILABLE] L3: 18 of 39

ABSTRACT:
This invention relates to certain polyamines found to be present in the
^_ venom ^_ of the Agelenopsis aperta spider. The polyamines of this
invention and the salts thereof antagonize excitatory amino acid
neurotransmitters, which neurotransmitters affect cells of various
organisms, and are useful in antagonizing said neurotransmitters, per se,
in the treatment of excitatory amino acid neurotransmitter mediated
diseases and conditions and in the control of invertebrate pests. This
invention also relates to compositions comprising said polyamines and
salts thereof.

19. 5,034,317, Jul. 23, 1991, Enzyme controlled release system and
organic conjugate reactant; Michael J. Arnost, et al., 435/18, 4, 6, 14,
19, 21 [IMAGE AVAILABLE]

US PAT NO: 5,034,317 [IMAGE AVAILABLE] L3: 19 of

ABSTRACT:
The present invention provides an enzyme controlled release system and
prepared reactant by which an identifiable molecule may be released on
demand through the action of an active enzyme. The controlled release
system is useful for detection of an analyte of interest present in a
test sample in picogram per liter quantities and may be employed in a
variety of different modes of use including immunoassays, enzyme
amplification systems and the release of pharmacologically active

ligands.

20. 5,021,576, Jun. 4, 1991, 2-Anilino phenylacetic acid derivatives;
Amedeo A. Failli, et al., 546/174, 175 [IMAGE AVAILABLE]

US PAT NO: 5,021,576 [IMAGE AVAILABLE] L3: 20 of 39

ABSTRACT:
There are disclosed compounds of the formula ##STR1## wherein R is
hydroxy, lower alkoxy or lower alkoxyamino;
R.sup.1 is hydrogen or A(CH.sub.2).sub.n O--;
R.sup.2 is hydrogen or A(CH.sub.2).sub.n O--, with the proviso that one
of R.sup.1 and R.sup.2 is A(CH.sub.2).sub.n O-- and the other is

hydrogen;
n is 1-2;
A is phenoxyethyl, phenoxyphenyl or a group having the formula
##STR2##
X is --N-- or ##STR3## Z is ##STR4## R.sup.3 is hydrogen, lower alkyl
or phenyl; R.sup.4 is hydrogen or lower alkyl; or
R.sup.3 and R.sup.4 taken together form a benzene ring;
R.sup.5 is hydrogen or lower alkyl;
R.sup.6 is hydrogen, halo or lower alkyl;
and the pharmacologically acceptable salts thereof, and their use in the
treatment of inflammatory conditions, such as rheumatoid arthritis,
ulcerative colitis, psoriasis and other immediate hypersensitivity
reactions; in the treatment of leukotriene-mediated naso-bronchial
obstructive air-passageway conditions, such as allergic rhinitis,

cytoprotective
agents.

21. 5,013,830, May 7, 1991, Compounds for the cleavage at a specific
position of RNA, oligomers employed for the formation of said compounds,
and starting materials for the synthesis of said oligomers; Eiko Ohtsuka,
et al., 536/27, 28, 29 [IMAGE AVAILABLE]

US PAT NO: 5,013,830 [IMAGE AVAILABLE] L3: 21 of 39

ABSTRACT:
There is disclosed a compound having a double chain which is composed of
an RNA (+chain) and a complementary DNA (-chain), wherein a portion of
the DNA (-chain) has been replaced by an RNA or a derivative thereof, and
wherein, when the compound is subjected to the action of an enzyme having
a ribonuclease H activity, it is possible to preferentially cleave the
RNA (+chain) in a position corresponding to the unsubstituted portion of
the DNA (-chain). The compound can thus be used for the preferential
cleavage of a phosphodiester bond in a specific position of RNA.
Accordingly, the invention provides a useful means for preparing, for

instance, a deletion mutant. There is also disclosed a mixed oligomer
which comprises an oligomer of RNA or a derivative thereof and a DNA
oligomer, wherein the RNA oligomer or a derivative thereof is conjugated
to the DNA oligomer via a phosphate diester linkage between the
5'-hydroxyl group and the 3'-hydroxyl group in the ribose or deoxyribose
moiety. There is further disclosed a nucleoside derivative of a given
general formula for use as a starting material.

22. 4,960,712, Oct. 2, 1990, System and method for complement pathway
analysis; Argyrios N. Theofilopoulos, et al., 436/501; 435/965, 973;
436/507, 512, 536, 539, 548, 804, 821 [IMAGE AVAILABLE]

US PAT NO: 4,960,712 [IMAGE AVAILABLE] L3: 22 of 39

ABSTRACT:
The present invention relates to systems and methods used to assay for
particular complement component fragments. The invention can be used to
determine the amount of a particular complement component fragment in a
sample. The fragment can be fluid phase or bound to an immune complex.
Generally, specific binding agents, such as antibodies, directed to the
complement component fragments and immune complexes are used in the
assay.

23. 4,946,788, Aug. 7, 1990, Purified immunoglobulin-related factor,
novel monoclonal antibodies, hybridoma cell lines, processes and
applications; Guy Delespesse, 530/388.22; 424/85.8; 435/7.5, 70.21,
172.2, 188, 240.27, 948, 954; 530/388.73, 391.3, 862, 865, 868; 935/95,
100, 102, 103, 104, 106, 107, 108, 110 [IMAGE AVAILABLE]

US PAT NO: 4,946,788 [IMAGE AVAILABLE] L3: 23 of 39

ABSTRACT:
The invention relates to novel purified human immunoglobulin E binding
factors (IgE-BFs), its individual optionally glycosylated proteins, and

fragments thereof, processes for the purification of IgE-BFs, novel
monoclonal antibodies to lymphocyte cellular receptors for IgE
(Fc.sub..epsilon. R) crossreacting with IgE-Fs, derivatives thereof,
processes for the preparation of these antibodies and their derivatives,
hybridoma cell lines that produce these antibodies, processes for the
preparation of said hybridoma cell lines, the use of the monoclonal
antibodies and their derivatives for the qualitative and quantitative
determination of IgE-BFs, test kits containing the monoclonal antibodies
and/or their derivatives, the use of the monoclonal antibodies for the
purification of IgE-BFs, the use of purified IgE-BFs, its individual
optionally glycosylated proteins and/or fragments thereof for the

preparations containing them. IgE-BFs and monoclonal antibodies reacting
with IgE-BF are important for the diagnosis and therapy of allergic
diseases.

24. 4,880,817, Nov. 14, 1989, O-functionalized derivatives of substituted isoquinolin-3-ols having cardiotonic and/or phosphodiesterase
fraction III inhibiting properties and/or renal vasodilating properties;
Ramesh M. Kanojia, et al., 514/309, 210, 235.2, 253; 544/128, 363;
546/141

US PAT NO: 4,880,817 L3: 24 of 39

ABSTRACT:
O-functional derivatives of substituted isoquinolin-3-ol compounds of the
general formula ##STRi## that exhibit cardiotonic and/or
phosphodiesterase fraction III inhibiting properties and/or renal

vasodilating are pharmacologically active in the treatment of cardiac
conditions. Methods for synthesizing and using the compounds are described.

25. 4,867,973, Sep. 19, 1989, Antibody-therapeutic agent conjugates;
John W. F. Goers, et al., 424/85.91, 85.8, 86, 87; 514/2, 6, 8;

530/388.7, 388.9, 391.9, 828, 864, 866; 930/10, 22

US PAT NO: 4,867,973 L3: 25 of 39

ABSTRACT:
This invention relates to antibody-therapeutic agent conjugates having a
therapeutic agent covalently attached to an antibody or antibody
fragment. Also described are methods for intermediates in the preparation
of antibody conjugates. Therapeutic in vivo methods utilizing such
antibody-therapeutic agent conjugates are described.

26. 4,774,318, Sep. 27, 1988, Snake ^_ venom ^_ growth arresting peptide;
Hans Marquardt, et al., 530/324, 325, 326, 856; 930/10, 260, DIG.821

US PAT NO: 4,774,318 L3: 26 of 39

ABSTRACT:
Novel cytotoxic agents are provided as small polypeptides related to a
low molecular weight peptide derived from Crotalus atrox. The compounds
may be used by themselves or in combination with other reagents, such as
antibodies, for inhibiting cell growth.

27. 4,769,320, Sep. 6, 1988, Immunoassay means and methods useful in
human native prothrombin and human abnormal prothrombin determinations;
Bruce E. Furie, et al., 435/7.92, 7.23, 7.4, 13, 810; 436/69, 536, 548,
808, 811, 815, 825; 530/381, 384, 388.25, 808

US PAT NO: 4,769,320 L3: 27 of 39

ABSTRACT:
Antibodies which form immune complexes with human native prothrombin
only, in the presence of mixtures of human native prothrombin and human
abnormal prothrombin as well as antibodies which form antibody antigen
complexes with human abnormal prothrombin in the presence of such

mixtures have been obtained. Immunoassay techniques are used for
qualitative and quantitative determinations of these antigens in

human
plasma or serum. Unique methods of obtaining the antibodies are described
including obtaining antibodies to native prothrombin by dissociation of
antigen antibody complexes formed in the presence of calcium ions with a
material having a greater affinity constant for binding with calcium ions
than does prothrombin. Dissociation of the complex in this manner yields
human native prothrombin antibodies which are specific and non-reactive
with human abnormal prothrombin. A process is described in which assays
are applied to the sensitive detection of vitamin K deficiency and
various forms of liver disease including hepatocellular carcinoma, and to
monitoring of anticoagulant therapy with sodium warfarin. The invention

from the
Department of Health and Human Services.

29. 4,721,439, Mar. 15, 1988, Snake ^_ venom ^_ growth arresting peptide;
Hans Marquardt, et al., 530/324; 424/85.91; 514/2, 12, 21; 530/350, 402;
435, 852; 930/10, 20, 260, DIG.821

US PAT NO: 4,721,439 L3: 29 of 29

ABSTRACT:
Novel cytotoxic agents are provided as small polypeptides related to a
low molecular weight peptide derived from Crotalus atrox. The compounds
may be used by themselves or in combination with other reagents, such as
antibodies, for inhibiting cell growth.

30. 4,714,725, Dec. 22, 1987, 4-nitrogen substituted isoquinolinol
compounds having cardiotonic, phosphodiesterase fraction III inhibiting
properties and/or renal vasodilating properties; Ramesh M. Kanojia, et
al., 514/309; 546/141

US PAT NO: 4,714,725 L3: 30 of 30

ABSTRACT:
Substituted 3-isoquinolinol compounds of the general formula
ABSTRIAN
that exhibit cardiotonic and/or phosphodiesterase fraction III inhibiting
properties and/or renal vasodilating are pharmacologically active in the
treatment of cardiac conditions. Methods for synthesizing and using these
compounds are described.

31. 4,675,287, Jun. 22, 1987, Monoclonal antibody directed to human
ganglioside GD.sub.2; Ralph A. Reisfeld, et al., 435/7.23; 424/85.8;
85.91; 435/7.92; 70.21; 172.2; 260.27; 948; 975; 424/510; 520; 810; 812;
530/387.5; 388.2; 388.85; 391.3; 808; 809; 866; 935/89, 95, 104, 107

US PAT NO: 4,675,287 L3: 31 of

ABSTRACT:
A non-human, mammalian monoclonal receptor produced and secreted by a
hybridoma having the ATCC accession number HB 8568 and methods of

preparing and using same, as well as diagnostics utilizing the receptor
are disclosed. The monoclonal receptor reacts with cells such as human
neuroectodermal tumors having ganglioside GD.sub.2 antigen expressed on
their cellular membrane surfaces.

31. 4,672,044, Jun. 9, 1987, Murine monoclonal antibody combining site
to human C3b receptor (CR1); Robert D. Schreiber, 436/501; 435/4, 7.21,
7.24, 7.25, 70.21, 172.2, 240.27, 810, 968, 975; 436/504, 506, 507, 512,
518, 536, 540, 548, 815, 821; 935/104, 110

US PAT NO: 4,672,044 L3: 31 of 39

ABSTRACT:
A murine monoclonal antibody combining site produced by a hybridoma
formed by fusion of cells from a myeloma cell line and lymphocytes that
produce antibodies that react (1) with isolated human C3b receptor and

(2) with C3b receptor-bearing cells from a mammal immunized with human
C3b receptor is disclosed.

32. 4,671,958, Jun. 9, 1987, Antibody conjugates for the delivery of
compounds to target sites; John D. Rodwell, et al., 424/85.91, 1.1, 85.8,
86, 87; 514/2, 6, 8; 530/389.6, 391.5, 391.9, 828, 864, 866 [IMAGE
AVAILABLE]

US PAT NO: 4,671,958 [IMAGE AVAILABLE] L3: 32 of 39

ABSTRACT:
A method is described for the covalent attachment of linker groups to
specific sites on antibody molecules directed against any desired target
antigen (tumor, bacterial, fungal, viral, parasitic etc.). These

linkers
can be attached via amide or ester bonds to compounds for delivery which
contain available amino or hydroxy groups (e.g., bioactive agents,
cytotoxic agents, dyes, fluors, radioactive compounds, etc.). In addition
the linkers can be incorporated into insoluble matrices for use in
separation schemes which are based upon antibody-antigen interactions.
The linkers may be designed so that they are susceptible to cleavage by
any one of the serum complement enzymes. When prepared according to the
methods described herein, the resulting modified antibody molecule
retains the ability to bind antigen and to fix serum complement. Thus,
when administered to a patient the antibody conjugate binds to its target
in vivo. As a result of the subsequent activation of the patient's serum
complement, the covalently attached compound will be specifically cleaved
at the target site by the proteolytic enzymes of the complement system.

33. 4,661,347, Apr. 28, 1987, Cytotoxic compositions; Hans J. Muller-Eberhard, et al., 424/85.91; 435/188; 530/388.85, 391.7, 391.9,
395, 402, 403, 404, 408

US PAT NO: 4,661,347 L3: 33 of 39

ABSTRACT:
A cytotoxic composition is described comprising a moiety having binding
affinity to a surface structure of a cell and coupled to a moiety having
activity as a structural subunit of C3/C5 convertase.

34. 4,642,284, Feb. 10, 1987, Method and system for detection of

complement pathway activation; Neil Cooper, et al., 435/7.94, 4, 7.4, 28,
965, 966, 971, 975; 436/512, 516, 520, 528, 529, 530, 536, 538, 540, 543,
544, 547, 808, 821

US PAT NO: 4,642,284 L3: 34 of 39

ABSTRACT:

A method and system for detecting and preferably measuring the presence
of an activated complement complex in a sample is discussed. The presence
of such an activated complex is indicative of complement pathway
activation and includes a first complement component and a second

complement component. The method uses a first binding agent specific to
the first complement component and a second binding agent specific to the
second complement component which when bound with the complex forms an
aggregate. The second specific binding agent includes a label whose
presence is used to detect and measure the amount of aggregate and
therefore activated complex in a sample. An assay system and aggregate
for use in an assay system are also discussed.

35. 4,517,303, May 14, 1985, Specific binding assays utilizing analyte-cytolysin conjugates; J. William Freytag, et al., 436/501; 435/4,
5, 7.21, 7.22, 7.23, 7.25, 7.31, 7.32, 7.5, 7.8, 7.9, 21, 36, 966, 972;
436/512, 520, 541, 803, 813, 815, 817, 827, 828, 829; 930/10, 240, 280,
DIG.821 [IMAGE AVAILABLE]

US PAT NO: 4,517,303 [IMAGE AVAILABLE] L3: 35 of 39

ABSTRACT:
A novel analyte-cytolysin conjugate and its use in a lipid vesicle
mediated measurement process is described for a wide variety of analytes
present at very low concentration. The method involves forming a reaction
system consisting of analyte, analyte specific binding agent,
analyte-cytolysin conjugate, and vesicles containing detectable marker
material in such proportions that uncombined conjugate alters the

permeability of the vesicles resulting in the release and quantitative
detection of marker material which can be correlated with the amount of
analyte initially present.

36. 4,454,226, Jun. 12, 1984, Enzymatic immunoassay; Majid Ali, et al.,

531

US PAT NO: 4,454,226 L3: 36 of 39

ABSTRACT:
An enzyme immunoassay for detecting an antigen in a biologic fluid or tissue which comprises contacting the fluid or tissue with an antibody specific for the antigen under binding conditions, at least one of the fluid or tissue and antibody having a solid component, contacting the resulting solid with a conjugate bindable with the antibody under binding conditions and determining the enzyme activity of the resulting solid phase is described. The conjugate is of peroxidase and an allergen, non-immunoglobulin protein or primary amino group containing drug having an average of 2-3 molecules of peroxidase per molecule of substance with an average molecular weight of about 30,000 daltons, prepared by reacting peroxidase previously treated with phenyl isothiocyanate and oxidized to form aldehyde groups with the substance to form a Schiff's base which is titrated with a reducing agent to form a stable conjugate.

37. 4,447,526, May 8, 1984, Homogeneous specific binding assay with carrier matrix incorporating specific binding partner; Patricia A. Rupchock, et al., 435/7.7; 422/56; 435/7.72, 7.92, 805, 971; 436/528, 530, 535, 537, 810

US PAT NO: 4,447,526 L3: 37 of 39

ABSTRACT:
A method for determining the presence of a ligand in, or the ligand binding capacity of a liquid test sample which includes the steps of (a) adding to the sample a conjugate of the ligand and a label, (b) contacting the sample with a test device containing reagents which in conjunction with the conjugate and ligand, are capable of producing a

[illegible]

28. 4,446,315, May 1, 1984, Adenosine 5'-triphosphate-4-carboxamide-thiazolylribofuranosyl, Victor E. Marquez, et al., 536/27, 29

US PAT NO: 4,446,315 L3: 28 of 30

ABSTRACT:
The present invention relates to the preparation of and the antitumor compound, adenosine 5'-(trihydrogen diphosphate) 5',5'-ester with 4-carboxamide-2-.beta.-D-ribofuranosylthiazole.

29. 4,430,495, Feb. 7, 1984, Process for preparing lincomycin and clindamycin ribonucleotides; Tom E. Patt, et al., 536/16.2, 16.2, 16.4, 16.5, 28, 29

US PAT NO: 4,430,495 L3: 29 of 30

ABSTRACT:
Novel and useful ribonucleotides of analogs of the well known antibiotics lincomycin and clindamycin. These ribonucleotides are unexpectedly highly active against Streptococcus hemolyticus and Staphylococcus aureus in vivo. These ribonucleotides are prepared by using resting cell or cell-free extracts of Streptomyces rochei, NRRL 3533, or cell-free extracts of Streptomyces coelicolor, NRRL 3532.

```
=> d his

     (FILE 'USPAT' ENTERED AT 11:34:27 ON 24 FEB 92)
L1            682 S VENOM OR ANTIVENIN
L2           2470 S FAB OR FAB2
L3             30 S L2 AND L1

=> s l2 and polyacrylamide
          12911 POLYACRYLAMIDE
L4            270 L2 AND POLYACRYLAMIDE

=> s l4 and (pepsin or papain)
           1012 PEPSIN
           1265 PAPAIN
L5            152 L4 AND (PEPSIN OR PAPAIN)
```

[illegible]

75. 4,897,466, Jan. 30, 1990, Human lymphoblastoid cell line and

hybridomas derived therefrom; James W. Larrick, et al., 424/85.8;

530/809; 935/107

=) t15 100 cit
'TL5' IS NOT A RECOGNIZED COMMAND

=) t 15 100 cit

100. 4,772,550, Sep. 20, 1988, Heterogeneous specific binding assay
employing an aggregatable binding reagent; Alfred C. Greenquist,
435/7.92; 7.5; 7.93; 7.94; 288; 805; 810; 436/503; 524; 529; 533; 534,
539; 808; 810; 824

=) t 15 125 cit

125. 4,614,793, Sep. 30, 1986, Hepatitis A--subunit antigen; Joseph V.
Hughes, et al., 530/350; 418; 806; 826; 930/223

=) t 15 140 cit

140. 4,429,008, Jan. 31, 1984, Thiol reactive liposomes; Frank J.
Martin, et al., 428/402.2; 424/1.1; 85.8; 88; 450; 436/501; 532; 829
[IMAGE AVAILABLE]

=) t 15 140 -152 cit ab
'-152' IS NOT A VALID FORMAT FOR FILE 'USPAT'
ENTER DISPLAY FORMAT (CIT):140-152
'140-152' IS NOT A VALID FORMAT FOR FILE 'USPAT'
YOU HAVE RECEIVED THIS ERROR MESSAGE 2 CONSECUTIVE TIMES

The following are valid formats:

PNO ----- Patent Number
PAT ----- Patent Number, Issue Date, and Current Original
Reference Classification
CIT ----- Patent Number, Issue Date, Title,
First Inventor Name, and Current Classifications
LEG ----- Patent Number, Issue Date, Title, Inventor, Assignee,
Appl. Number, Filing Date, Art Unit, Primary Examiner,
Legal Rep., Rule 47 Indicator, Attorney Reg. Number
REF ----- Classification and Reference Information
DATE ---- PCT Information and all dates from Front Page
PCT ----- Alias for the DATE Format
BIB ----- Alias for the LEG Format
FRO ----- Front Page Information, Art Unit, and Current
Classifications

ALL ----- Entire Patent and Key words assigned
FUL ----- Alias for the ALL Format
SPC ----- Alias for the ALL Format
CLS ----- Patent Number and Current Classification
PN ------ Patent Number
OCC ----- Occurrence Count
AB ------ Abstract
FD ------ Application Filing Date
AD ------ Application Filing Date
AN ------ Application Number
ART ----- Art Unit
AS ------ Assignee Information
ATT ----- Attorney, Agent or Firm
ASUM ---- Summary
CCLS ---- Current Classification
CLMS ---- Claims Information
D371 ---- PCT 371 Date
DD ------ Disclaimer Date
DETD ---- Detail Description
DRWD ---- Drawing Description
E102 ---- PCT 102(e) Date
ECL ----- Exemplary Claim Number
FREF ---- Foreign Patent References Cited
FS ------ Field of Search Subclasses
GI ------ Government Interest Text Data
ICLS ---- Issue Classification
IN ------ Inventor Information
IPC ----- International Classification
OREF ---- Other Publication References Cited
PARN ---- Parent Case Text Data
PD ------ Issue Date
PDDR ---- Number of Drawing Sheets

PPSP ---- Number of Specification Pages
PRIR ---- Foreign Application Priority
PTAN ---- PCT Number
PTFD ---- PCT Filing Date
PTPD ---- PCT Publication Date
PTPN ---- PCT Publication Number
REI ----- Reissue Data
REL ----- Related Application Data
TERM ---- Term Of Patent
TI ------ Title
UREF ---- U. S. Patent References Cited
XA ------ Assistant Examiner
XP ------ Primary Examiner
KEY ----- Keywords Identified for Patent
IF YOU REQUIRE FURTHER HELP, PLEASE CONTACT YOUR LOCAL HELP DESK
ENTER DISPLAY FORMAT (CIT):
ENTER DISPLAY FORMAT (CIT):cit

140. 4,429,008, Jan. 31, 1984, Thiol reactive liposomes; Frank J.
Martin, et al., 428/402.2; 424/1.1, 85.8, 88, 450; 436/501, 532,

[IMAGE AVAILABLE]

=) t 15 cit 140-152

140. 4,429,008, Jan. 31, 1984, Thiol reactive liposomes; Frank J.
Martin, et al., 428/402.2; 424/1.1, 85.8, 88, 450; 436/501, 532, 829
[IMAGE AVAILABLE]

141. 4,421,735, Dec. 20, 1983, Radiolabeled diagnostic compositions and
method for making the same; Edgar Haber, et al., 424/1.1, 9; 530/382,
389.1, 389.2, 389.7, 391.5, 392, 404, 405, 408, 409 [IMAGE AVAILABLE]

142. 4,400,376, Aug. 23, 1983, Immunological preparations; Arnold R.
Sanderson, 424/88, 85.8, 86, 87, 89, 91, 92; 436/543; 530/388.2, 388.73,
389.2, 389.4, 389.5, 389.6, 391.9, 405, 806, 807, 866

143. 4,375,972, Mar. 8, 1983, Heterogeneous chemiluminescent
immunoassays utilizing metallo porphyrin tag; Peter S. Forgione, et al.,
436/531, 546

144. 4,368,149, Jan. 11, 1983, Protein hybrid having cytotoxicity and
process for the preparation thereof; Yasuhiko Masuho, et al., 530/391.9;

424/85.91, 98; 530/389.6, 391.7, 866; 935/107

145. 4,366,241, Dec. 28, 1982, Concentrating zone method in
heterogeneous immunoassays; Henry K. Tom, et al., 435/7.91; 422/56;
435/5, 7.9, 7.92, 805, 810, 968, 975; 436/541, 800, 807

146. 4,363,758, Dec. 14, 1982, Cytotoxic protein hybrid and process for
the preparation thereof; Yasuhiko Masuho, et al., 530/391.9; 424/85.91,
88; 435/172.2; 530/370, 379, 389.6, 391.7, 866; 935/107, 108

147. 4,357,273, Nov. 2, 1982, Antitumor protein hybrid and process for
the preparation thereof; Yasuhiko Masuho, et al., 530/391.9; 435/172.2;
514/12; 527/203; 530/389.3, 389.7, 806, 825, 866; 935/107, 108

148. 4,350,626, Sep. 21, 1982, Antitumor hybrid and process for the
preparation thereof; Yasuhiko Masuho, et al., 530/391.9;

424/178.2;
530/389.6; 514; 935/107

140. 4,496,027, Oct. 29, 1984, Pure intravenous human red animal
globulin; Richard M. Davis; 530/389.5; 424/85.8; 530/829

150. 4,672,506, Jun. 9, 1984, Purification of reagents by
disulfide
immobilization; Moshe Schwarzberg; 436/512; 359/300; 424/1.1; 99;
435/4;
514; 514; 660; 436/513; 514; 800, 935; 530/389.1; 389.3; 391.1;
391.3;
424; 412; 813; 814 [IMAGE AVAILABLE]

151. 4,822,402, Nov. 11, 1980, Reagents and method employing
channeling;
Edward T. Maggio, et al., 435/5; 7.7; 7.91; 960; 436/537; 805

152. 4,036,945, Jul. 19, 1977, Composition and method for
visualizing
the size and location of myocardial infarcts; Edgar Haber;
424/1.1;
128/654; 250/303; 424/9 [IMAGE AVAILABLE]

=\ t 15 cit ab 140-152

140. 4,420,000, Jan. 21, 1984, Thiol reactive liposomes; Frank
J.
Martin, et al., 436/400.2; 424/1.1; 85.8; 88; 450; 436/501; 532;
829
[IMAGE AVAILABLE]

US PAT NO: 4,420,000 [IMAGE AVAILABLE] L5: 140 of
152

ABSTRACT:
Liposomes are provided which have a plurality of thiol reactive
groups
extending outward of the liposomal bilayer. The liposomes form
stable
covalent bonds with ligands having thiol groups, such as ^_ Fab
^_ '
fragments. Particularly preferred liposomes include maleimide
moieties as
the thiol reactive groups. The thiol reactive liposomes are
useful in
applications in agglutination assays, such as blood typing and
tissue
matching
inhibitions, and targeting to specific cells.

141. 4,421,735, Dec. 20, 1983, Radiolabeled diagnostic
compositions and

method for making the same; Lugal Maddy, et al., 424/1.1; 530/382,
389.1, 389.2, 389.7, 391.5, 392, 404, 405, 408, 409 [IMAGE AVAILABLE]

US PAT NO: 4,421,735 [IMAGE AVAILABLE] L5: 141 of 152

ABSTRACT:
Protein molecules are covalently bonded to a chelating agent which in turn binds a radioactive molecule. Prior to binding, the radioactive molecule is reduced with dithionite ion and then mixed with protein at a pH of 7.0 to about 8.0.

142. 4,400,376, Aug. 23, 1983, Immunological preparations; Arnold R. Sanderson, 424/88, 85.8, 86, 87, 89, 91, 92; 436/543; 530/388.2, 388.73, 389.2, 389.4, 389.5, 389.6, 391.9, 405, 806, 807, 866

US PAT NO: 4,400,376 L5: 142 of 152

ABSTRACT:

An immunological preparation of an antigenic material in combination with a major histocompatibility complex antigen, which is itself in the form of complex with a protein with which it is normally associated in nature or with a modified form of such protein which retains the epitope thereof intact, said antigenic material being attached to the protein of the complex through antibody to that protein, is disclosed as being useful for the production of an immunogenic response in human or veterinary use.

143. 4,375,972, Mar. 8, 1983, Heterogeneous chemiluminescent immunoassays utilizing metallo porphyrin tag; Peter S. Forgione, et al., 436/531, 546

US PAT NO: 4,375,972 L5: 143 of 152

ABSTRACT:
A conjugate for use in the detection and quantification of antibodies and antigens in body fluids by immunoassay procedures ...

chemiluminescent
immunoassay procedures utilizing the conjugate. The conjugate is capable
of reacting with an antigen or an antibody or both and includes a tag
capable of catalyzing a chemiluminescent reaction. The conjugate may be
an antibody or an antigen to which a metallo porphyrin tag is attached
and preferably comprises immunoglobulin to which hemoglobin is attached.

144. 4,368,149, Jan. 11, 1983, Protein hybrid having cytotoxicity and
process for the preparation thereof; Yasuhiko Masuho, et al., 530/391.9;
424/85.91, 98; 530/389.6, 391.7, 866; 935/107

US PAT NO: 4,368,149 L5: 144 of 152

ABSTRACT:
A protein hybrid having cytotoxicity obtained by covalently bonding an
immunoglobulin or its fragment, which is capable of binding selectively
to an antigen possessed by a cell to be destroyed, to a protein, which is
obtained from Momordica charantia and has an activity to terminate
protein synthesis. This protein hybrid displays remarkable cytotoxicity

against target cells.

145. 4,366,241, Dec. 28, 1982, Concentrating zone method in
heterogeneous immunoassays; Henry K. Tom, et al., 435/7.91; 422/56;
435/5, 7.9, 7.92, 805, 810, 968, 975; 436/541, 900, 807

US PAT NO: 4,366,241 L5: 145 of 152

ABSTRACT:
Method and apparatus are provided for performing immunoassays employing a
device comprising a relatively small test zone referred to as an
immunosorbing zone, and a relatively large liquid absorbing zone in
liquid receiving relationship with said immunosorbing zone. The
immunosorbing zone includes a member of an immunological pair
("mip")--ligand and antiligand--bound to a support.
A signal producing system is employed in conjunction with said device

having as one component a signal label bound to a ligand, the signal

producing system provides for production of a detectible signal in the
immunosorbing zone in relation to the amount of analyte in a sample.

146. 4,363,758, Dec. 14, 1982, Cytotoxic protein hybrid and process for
the preparation thereof; Yasuhiko Masuho, et al., 530/391.9; 424/85.91,
88; 435/172.2; 530/370, 379, 389.6, 391.7, 866; 935/107, 108

US PAT NO: 4,363,758 L5: 146 of 152

ABSTRACT:
A cytotoxic protein hybrid obtained by covalently bonding an
immunoglobulin or its fragment, which is capable of linking selectively
with an antigen possessed by a cell to be destroyed, to a protein, which
is obtained from Phytolacca americana and has an activity to terminate
protein synthesis. This protein hybrid displays remarkable cytotoxicity
against target cells.

147. 4,357,273, Nov. 2, 1982, Antitumor protein hybrid and process for
the preparation thereof; Yasuhiko Masuho, et al., 530/391.9; 435/172.2;
514/12; 527/203; 530/389.3, 389.7, 806, 825, 866; 935/107, 108

US PAT NO: 4,357,273 L5: 147 of 152

ABSTRACT:
Antitumor protein hybrid, composed of a moiety which is substantially the
fragment ^_ Fab ^_ of an anti-.alpha.-fetoprotein antibody and a moiety
which is substantially the fragment A of a diphtheria toxin, which is
expressed by the following formula (I):

^_ Fab ^_ --(S.sub.1 --(X).sub.n --S.sub.2 --FA).sub.m
(I)

(where ^_ Fab ^_ indicates a moiety which is substantially the fragment
^_ Fab ^_ of an anti-.alpha.-fetoprotein antibody; FA indicates a moiety
which is substantially the fragment A of diphtheria toxin; X indicates a

atoms,
S.sub.1 indicating a sulfur atom arising from the disulfide bond (--S--S--bond) in an anti-.alpha.-fetoprotein antibody and S.sub.2 a
sulfur atom arising from the disulfide bond in a diphtheria toxin; n
stands for 0 or 1 and m stands for an integer of 1 to 5). This antitumor
protein hybrid has remarkable and specific cytotoxicity against tumor
cells.

148. 4,350,626, Sep. 21, 1982, Antitumor hybrid and process for the
preparation thereof; Yasuhiko Masuho, et al., 530/391.9; 435/172.2;
530/389.6, 866; 935/107

US PAT NO: 4,350,626 L5: 148 of 152

ABSTRACT:
Antitumor protein hybrid, composed of a moiety which is substantially the
fragment ^_ Fab ^_ of an antitumor immunoglobin and a moiety which is the
subunit A of ricin, which is expressed by the following formula (I):



(I)

(where ^_ Fab ^_ indicates a moiety which is substantially the fragment
^_ Fab ^_ of an antitumor immunoglobin; RA indicates a moiety which is the
subunit A of ricin; X indicates a divalent organic radical; S.sub.1 and
S.sub.2 are both sulfur atoms, S.sub.1 indicating a sulfur atom arising
from the disulfide bond (--S--S-- bond) in an immunoglobulin and S.sub.2
a sulfur atom arising from the disulfide bond in ricin; n stands for 0 or
1 and m stands for an integer of 1 to 5). This antitumor protein hybrid
has remarkable and specific cytotoxicity against tumor cells.

149. 4,296,027, Oct. 20, 1981, Pure intravenous human and animal gamma
globulins; Richard M. Condie, 530/390.5; 424/85.5; 530/830

US PAT NO: 4,296,027 L5: 149 of 152

ABSTRACT:
Isolated and purified natural, unaltered, undenatured immune gamma
globulin (IgG) for intravenous administration prepared from animal blood
plasma, especially human. The products are characterized by high yield
and high purity. They are unfragmented and unaggregated, i.e., natural
preparation.

150. 4,272,506, Jun. 9, 1981, Purification of reagents by disulfide
immobilization; Moshe Schwarzberg, 436/512; 250/302; 424/1.1, 88; 435/4,
962, 964, 968; 436/513, 546, 800, 825; 530/389.1, 389.3, 391.1, 391.3,
404, 413, 813, 861 [IMAGE AVAILABLE]

US PAT NO: 4,272,506 [IMAGE AVAILABLE] L5: 150 of 152

ABSTRACT:
A method is provided for preparing immunoassay reagents involving labeled
members of specific binding pairs substantially enriched relative to
contaminating labeled materials. The method involves conjugating a member
of a specific binding pair to a support by a covalent bond which is
cleavable under mild conditions to provide a binding pair

member-support
conjugate. Combining the binding pair member-support conjugate with a
labeled composition containing the reciprocal member of the binding pair,
so that the labeled reciprocal member becomes bound to the support
through the binding of the specific binding pair. Separating the support
to which is bound the labeled member from the remaining labeled material
and then cleaving the bond joining the labeled specific binding pair to
the support to provide labeled reagent for immunoassays. In particular,
an antibody is linked to a support by disulfide linkage and a composition
containing the reciprocal antigen to the antibody is labeled with a
chromophore, particularly fluorescer. The support is freed of labeled

link
cleaved to provide labeled reagent for immunoassays.

151. 4,233,402, Nov. 11, 1980, Reagents and method employing channeling;
Edward T. Maggio, et al., 435/5, 7.7, 7.91, 968; 436/537, 805

US PAT NO: 4,233,402 L5: 151 of 152

ABSTRACT:
Method and compositions are provided for chemical analysis of an analyte
which is a member of a specific binding pair of organic substances
consisting of ligand and ligand receptor (antiligand). The method

involves bringing together the following reagents with the analyte in an
aqueous assay medium under mild conditions.
The first reagent is a conjugate of a member of the specific binding pair
with a chemical entity which provides a means for chemically changing the
concentration of a compound which acts as a signal mediator. The second
reagent is the signal mediator precursor. The third reagent is a
conjugate of a member of the specific binding pair with a component of a
signal producing system of which system the signal mediator is a member.
The amount of signal which can be detected is affected by the

local
concentration of the signal mediator. By bringing the reagents together
in the presence of analyte, where the signal mediator concentration
changing means is brought together in a microenvironment with the

conjugated signal producing system component, localized concentrations of
the signal mediator can be created which differ from the gross
concentration of the signal mediator in the assay medium. The degree to
which the signal mediator concentration changing means is in close
proximity to the signal producing means in a microenvironment will affect
the observed signal. By appropriate choice of the two conjugates in
conjunction with the analyte, the observed signal can be related to the
amount of analyte in the medium.

conjugates in
specific proportions to substantially optimize the assay sensitivity. The
combinations are provided as kits, where ancillary reagents can also be
included, so as to simplify the combination of reagents, as well as
provide for more accurate measurements and relative proportions of
reagents.

152. 4,036,945, Jul. 19, 1977, Composition and method for determining
the size and location of myocardial infarcts; Edgar Haber, 424/1.1;
128/654; 250/303; 424/9 [IMAGE AVAILABLE]

US PAT NO: 4,036,945 [IMAGE AVAILABLE] L5: 152 of 152

ABSTRACT:
Radioactive labelled antibody for cardiac myosin is injected
intravenously after cardiac occlusion and is specifically absorbed in
infarcted myocardium, as are radioactive labelled lower molecular weight
fragments of the antibody such as (^_ Fab ^_ ').sub.2, (^_ Fab ^_ '), and (Fv).
The location and size of the myocardial infarct can be determined by
measuring the intensity and location of radioactive emission externally

of the heart.

=)